Page last updated: 2024-08-21

indazoles and Kidney Neoplasms

indazoles has been researched along with Kidney Neoplasms in 551 studies

Research

Studies (551)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.18)	18.7374
1990's	1 (0.18)	18.2507
2000's	23 (4.17)	29.6817
2010's	448 (81.31)	24.3611
2020's	78 (14.16)	2.80

Authors

Authors	Studies
Adomi, S; Banno, E; De Velasco, MA; Fujimoto, S; Fujita, K; Hashimoto, M; Inoguchi, S; Kikuchi, T; Minami, T; Mori, Y; Nakayama, T; Nishimoto, M; Nose, K; Nozawa, M; Saito, Y; Shimizu, N; Uemura, H; Yoshimura, K	1
Biswas, B; Chen, L; Chikatapu, C; Chung, HJ; Danchaivijitr, P; Erman, M; Hashem, T; Ingles, S; Kanesvaran, R; Karabulut, B; Lim, CS; Slimane, K; Wong, YF	1
Chin, S; Choi, JW; Kim, SG; Kim, YS; Yoo, JJ	1
Krens, SD; Mulder, SF; van Erp, NP	1
Álvarez-Fernández, C; Ángel Climent, M; Castellano, DE; Durán, I; García Carbonero, I; García-Del-Muro, X; García-Donas, J; Gil-Martin, M; González Del Alba, A; Hernández, AG; Mellado, B; Perez-Gracia, JL; Virizuela, JA	1
Farrugia, D; Fife, K; Hodgkins, AM; MacDonald-Smith, C; Pirrie, S; Porfiri, E; Stubbs, C; Vasudev, N; Zarkar, A	1
Amaro, F; Bastos, ML; Carvalho, M; Guedes de Pinho, P; Pinto, J; Pisoeiro, C; Valente, MJ	1
Alfsen, GC; Farkas, L; Geisler, J; Kristensen, VN; Müller, S; Naji, F; Nilsen, FS; Oldenburg, J; Puco, K; Tahiri, A	1
Chung, HS; Kim, SH; Kwon, TG; Lee, JL; Park, SH; Shim, BY; Shin, SJ	1
Connell, W; MacIsaac, M; Wu, K	1
Alam, S; Ghosh-Ray, S; Gogbashian, A; Lakhani, A; Nathan, P; Padhani, A; Sharma, A	1
Aoyama, T; Azuma, K; Furutani, R; Hama, T; Hashimoto, K; Hiraide, M; Ito, K; Kobayashi, K; Nakano, K; Okawa, T; Sato, H; Sugiyama, E; Suzuki, K; Tajima, M; Takahashi, S; Tomomatsu, J; Yuasa, T	1
Banna, GL; Brighi, N; Brunelli, M; Buti, S; Caffo, O; Cattrini, C; Corianò, M; De Giorgi, U; Fornarini, G; Giannarelli, D; Giudice, GC; Kinspergher, S; Malgeri, A; Mennitto, A; Puglisi, S; Rametta, A; Rebuzzi, SE; Roviello, G; Santoni, M; Scartabellati, G; Signori, A; Stellato, M; Tommasi, C; Verzoni, E	1
Carducci, MA	1
Hashida, T; Hirabatake, M; Ikesue, H; Kawakita, M; Morimoto, M; Muroi, N; Yamasaki, T; Yoshino, S	1
Anai, S; Eto, M; Hara, H; Hara, T; Ito, YM; Kimura, T; Kitamura, H; Kojima, T; Minami, K; Mitsuzuka, K; Miyauchi, Y; Morizane, S; Murai, S; Nakagomi, H; Nakai, Y; Nishiyama, H; Ohba, K; Osawa, T; Ozawa, M; Shiina, H; Shimazui, T; Shindo, T; Shinohara, N; Takahashi, A; Takeuchi, A; Tamura, K; Ueda, K; Uemura, M; Yokomizo, A; Yoshimura, K	1
Du, H; He, S; Sun, Y; Wang, L; Yu, X	1
Costa, RSD; Couto, DHN; Meirelles, IO	1
Balgetir, F; Er, MB; Gonen, M; Yildirim, N	1
Arranz, JA; Bellmunt, J; Calvo, A; Del Alba, AG; Del Muro, XG; Esteban, E; Etxaniz, O; Gallardo, E; Guix, M; Larriba, JLG; Maroto, P; Redrado, M; Sepúlveda, JM	1
Aspinall, SL; Becker, D; Cunningham, FE; Geraci, MC; Good, CB; Heron, BB; Lee, S; Prasad, V; Zhao, X	1
Brown, JN; Hammond, JM; Lee, S; Sneed, GT	1
Bjarnason, GA; Choueiri, TK; Dezzani, L; Grünwald, V; Han, J; Hutson, TE; Kollmannsberger, C; Motzer, RJ; Porta, C; Sternberg, CN; Tannir, NM	1
Chamberlain, S; Mole, DR; Protheroe, A; Purshouse, K; Soares, M; Tuthill, M	1
Campos-Gomez, S; Chacon, M; Del Castillo, C; Dezzani, L; Jenkins, M; Lema Medina, M; Lerzo, G; Lopera, D; Martin, A; Queiroz Muniz, D; Ratto, B; Salman, P; Signorovitch, J; Yang, H; Zhao, J	1
Bøttger, P; Donskov, F; Fink, TL; Hamilton-Dutoit, S; Henriksen, JN; Hermansen, CK; Ladefoged, SA; Nissen, PH	1
Altavilla, D; Cannavò, SP; Riso, G; Vaccaro, M	1
de Geeter, P; Decker, T; Quiering, C; Resch, A; Schmitz, S; Schostak, M	1
Cao, X; Gao, W; Jin, L; Poole, A; Ratto, B; Ravichandran, S; Swallow, E; Tang, D; Vogelzang, NJ	1
Aktepe, O; Bas, O; Erman, M; Guven, D; Kertmen, N; Kılıc, L; Ozbek, A	1
Akgül Babacan, N; Akın Telli, T; Alan, Ö; Alsan Çetin, İ; Arıkan, R; Başoğlu Tüylü, T; Çiçek, FC; Dane, F; Demircan, NC; Ercelep, Ö; Ergelen, R; Kaya, S; Öztürk, MA; Tinay, İ; Yumuk, PF	1
Choi, H; Gupta, S; Kang, HC; Matrana, MR; Sun, J; Tannir, NM	1
Giuffrida, D; Puglisi, C; Puliafito, I; Russo, A; Sciacca, D	1
Albuquerque, EV; Bastos, DA; Bonadio, RC; Cavalcante, A; Coelho, RF; Cordeiro, MD; Nahas, WC; Pontes, J; Sarkis, AS; Sierra, PS	1
Beijnen, JH; de Vries, N; Groenland, SL; Huitema, ADR; Koolen, SLW; Mathijssen, RHJ; Rosing, H; Steeghs, N; Thijssen, B; van Eerden, RAG; Verheijen, RB	1
Botikova, A; Dats, I; Dutka, I; Gazdikova, K; Kruzliak, P; Kubatka, P; Mytsyk, Y; Pasichnyk, S; Skrzypczyk, M; Urdzik, P; Uteuliyev, Y; Vorobets, D	1
Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M	1
Chen, L; Cheng, B; Cui, X; Gan, S; Hong, T; Li, J; Wang, C; Wang, Y; Zhang, J; Zuo, L	1
Endo, M; Harabayashi, T; Hiraga, H; Nagamori, S; Sugawara, M; Takekuma, Y; Tanaka, H	1
Bhutani, G; Emamekhoo, H; Kyriakopoulos, CE; Matkowskyj, KA; Zarling, L; Ziemlewicz, T	1
Guo, J; He, Z; Huang, Y; Jin, J; Qin, S; Ren, X; Sheng, X; Wang, B; Wang, J; Ye, D; Zhang, X; Zhou, A; Zhou, F	1
Božina, N; Kuruc Poje, D; Šimičević, L; Žabić, I	1
Adachi, H; Ito, A; Kawasaki, Y; Kikuchi, M; Mano, N; Takasaki, S	1
Albersen, M; Baldewijns, M; Beuselinck, B; Bourgain, C; Debruyne, PR; Haaker, L; Laenen, A; Laguerre, B; Lerut, E; Oudard, S; Renders, I; Rioux-Leclercq, N; Roussel, E; Tryssesoone, L; Van den Bulck, H; Verbiest, A; Wynendaele, W	1
Achkhanian, J; Nowak-Sliwinska, P; Rausch, M; Rotari, A; Weiss, A	1
Albersen, M; Baldewijns, M; Bechter, O; Beuselinck, B; Poncelet, R; Roussel, E; Spriet, I; Tack, J; Van De Sijpe, G; Van Nieuwenhuyse, T	1
Biró, K; Budai, B; Géczi, L; Gyergyay, F; Kiss, E; Küronya, Z; Ladányi, A; Martin, T; Nagyiványi, K; Szőnyi, MD	1
Bastos, DA; Bonadio, RRC; de Azevedo Souza, MCL; Dzik, C; Faraj, SF; Isaacsson Velho, P; Muniz, DQB; Nader Marta, G; Nardo, M	1
Azzouz, F; Braychenko, E; Elaidi, R; Epaillard, N; Moreira, M; Oudard, S; Simonaggio, A; Sun, CM; Thibault, C; Vano, YA	1
Feng, C; Li, Y; Shen, Y; Wen, H; Zhu, Z	1
Harada, Y; Kakimoto, S; Shimizu, T	1
Eisen, T; Fife, K; Gordon, J; Hawkins, R; Hurst, M; Matakidou, A; Naicker, N; Nolasco, S; Wang, M	1
de Geeter, P; Goebell, PJ; Grünwald, V; Herrmann, E; Hogrefe, C; Marschner, N; Merling, M; Panic, A; Potthoff, K; Staehler, M; Vannier, C	1
Barzaghi, P; Perego, G; Petrelli, F; Vavassori, I	1
Chun, FKH; Deuker, M; Karakiewicz, PI	1
Buckle, A; McLean, L; Siva, S; Tran, B; Zhong, YY	1
Claps, M; Di Maio, M; Grassi, P; Guadalupi, V; Martinetti, A; Mennitto, A; Procopio, G; Raimondi, A; Sepe, P; Sottotetti, E; Stellato, M; Verzoni, E; Zattarin, E	1
Albersen, M; Baldewijns, M; Beuselinck, B; Caruso, S; Couchy, G; García-Donas, J; Graña-Castro, O; Laenen, A; Rodriguez-Antona, C; Roussel, E; Schöffski, P; Van Hoef, V; Verbiest, A; Wozniak, A; Zucman-Rossi, J	1
Basso, U; Bergo, E; Bimbatti, D; Brunello, A; Lamberti, E; Maruzzo, M; Pierantoni, F; Tierno, G; Zagonel, V	1
Bex, A; Hofmann, F; Hwang, EC; Lam, TB; Ljungberg, B; Marconi, LS; Yuan, Y	1
Capri, S; Condorelli, C; Kalra, M; Khare, A; Modi, N; Porta, C; Premoli, E; Ratto, B	1
Beckermann, KE; Bortone, DS; Davis, NB; Ferguson, JE; Haake, SM; Karam, JA; Kim, WY; Maygarden, SJ; Milowsky, MI; Moore, DT; Parker, JS; Powles, T; Rathmell, WK; Vincent, BG; Wallen, EM; Whisenant, JG; Wood, CG	1
Basso, U; Bersanelli, M; Boccardo, F; Caffo, O; Cartenì, G; De Giorgi, U; Fornarini, G; Galli, L; Mosca, A; Naglieri, E; Porta, C; Procopio, G	1
Dicaudo, DJ; Karlin, N; Mangold, AR; Nafissi, NN; Pittelkow, MR	1
Eto, M; Hara, T; Ito, YM; Kashiwagi, A; Kawasaki, Y; Kitamura, H; Kojima, T; Minami, K; Miyauchi, Y; Morizane, S; Morooka, D; Murai, S; Murakami, M; Nakagomi, H; Nakai, Y; Nishiyama, H; Ohba, K; Osawa, T; Ozawa, M; Sazuka, T; Shimazui, T; Shinohara, N; Sugimoto, M; Takeuchi, A; Tomida, R; Ueda, K; Uemura, M; Yamamoto, Y; Yasumoto, H	1
Aimone, P; Choueiri, TK; Chowdhury, S; Doehn, C; Donskov, F; Gross-Goupil, M; Haas, N; Izquierdo, M; Kopyltsov, E; Lee, JL; Lim, HY; McDermott, R; Melichar, B; Michael, A; Motzer, RJ; Reaume, MN; Rini, B; Russo, P; Stenzl, A; Sternberg, CN; Varlamov, S; Wood, L; Zemanova, M; Zhang, H	1
Bondarenko, A; Borisov, P; Tishova, Y; Tsimafeyeu, I; Zakurdaeva, K; Zukov, R	1
Dahlem, R; Fisch, M; Fühner, C; Hillemacher, T; Janisch, F; Kienapfel, C; Klotzbücher, T; Marks, P; Meyer, CP; Mori, K; Mostafei, H; Rink, M; Shariat, SF; Yu, H	1
Armstrong, AJ; Brown, LC; Campbell, MT; Corn, P; Economides, M; Gao, J; Garmezy, B; George, DJ; Gupta, RT; Harrison, MR; Jonasch, E; Kao, C; Kinsey, EN; Laccetti, AL; Msaouel, P; Shah, A; Tannir, N; Venkatesan, A; Xiao, L; Zhang, T; Zurita-Saavedra, A	1
Afable, M; Aljumaily, R; Bendell, J; Drakaki, A; Ferry, D; Hung, A; Kim, JS; Naing, A; Papadopoulos, KP; Tannir, NM; Wong, DJ	1
Cao, W; Chen, J; Gao, S; Gao, Y; Ju, G; Ren, F; Wu, W; Wu, Z; Xiao, C; Xu, C	1
Fujisawa, M; Hara, T; Harada, K; Suzuki, K; Terakawa, T	1
Maruo, K; Tabata, H; Takagi, Y; Takahashi, A; Takayanagi, A	1
Brezinová, B; Chovanec, M; Dubovan, P; Gomolčáková, J; Jurišová, S; Mardiak, J; Mego, M; Rejlekova, K	1
Allaf, M; Ged, Y; Pierorazio, P; Singla, N	1
Aimone, P; Arkenau, T; Chowdhury, S; Hawkins, R; Infante, JR; McDermott, DF; Naeije, I; Perini, R; Reising, A; Voskoboynik, M; Voss, MH	1
Chisti, MM; Solano, C; Thapa, S	1
Bedognetti, D; Castelli, C; Chaussabel, D; Cova, A; de Braud, F; De Cecco, L; Dugo, M; Huber, V; Lalli, L; Procopio, G; Ratta, R; Rinchai, D; Rivoltini, L; Rodolfo, M; Roelands, J; Squarcina, P; Vallacchi, V; Verzoni, E	1
Borikun, TV; Pikul, MV; Rossylna, OV; Semko, SL; Stakhovsky, EO; Vitruk, Yu V; Voylenko, OA; Yalovenko, TM; Zadvornyi, TV	1
Endo, M; Kanno, N; Nakahashi, K; Numahata, K; Shiikawa, M; Shiono, S	1
Bendová, B; Büchler, T; Fiala, O; Filipovský, J; Fínek, J; Hora, M; Ostašov, P; Rozsypalová, A; Šorejs, O; Šustr, J; Trávníček, I	1
Agarwal, N; Appleman, LJ; Bhavsar, NA; Borham, A; Costello, BA; Fishman, MN; Gartrell, BA; George, DJ; Hammers, HJ; Harrison, MR; Hussain, A; Hutson, TE; Jim, H; Kyriakopoulos, CE; Mardekian, J; Molina, AM; Pachynski, RK; Pal, SK; Ryan, CW; Stadler, WM; Tsao, CK; Vaishampayan, U; Zakharia, Y	1
Aktas, BY; Kilickap, S; Koksal, D; Koylu, B; Tekin, F	1
Bair, AH; Cisar, L; Fishman, MN; Gruenwald, V; Hariharan, S; Hutson, TE; Jonasch, E; Michaelson, MD; Rini, BI; Rosbrook, B; Tarazi, J; Tomita, Y	1
Amantea, MA; Friberg, LE; Karlsson, MO; Schindler, E	1
Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L	1
Gandhi, S; George, S; Pandey, M	1
Fehnel, CR; Miller-Patterson, C	1
Bouchet, S; Calcagno, F; Devillard, N; Mouillet, G; Orillard, E; Royer, B; Thiery-Vuillemin, A	1
Cisar, L; Hutson, TE; Jiao, X; MacLean, EA; Wilson, T	1
Araki, K; Fujikura, M; Koshikawa, H; Kurita, A; Suzuki, M; Tsukie, T	1
Albiges, L; Bacciarelo, G; Brard, C; Escudier, B; Fizazi, K; Guida, A; Lassau, N; Le Teuff, G; Loriot, Y; Massard, C; Matias, M	1
Boyle, H; Brachet, PE; Coquan, E; Dugué, AE; Escudier, B; Helissey, C; Johnson, AC; Joly, F; Laguerre, B; Matias, M; Molinier, A; Mourey, L	1
Ardizzoni, A; Berardi, R; Bersanelli, M; Biasco, E; Buti, S; Cossu Rocca, M; De Giorgi, U; Fornarini, G; Galli, L; Guida, A; Iacovelli, R; Lolli, C; Masini, C; Massari, F; Mosca, A; Nolè, F; Pastorino, A; Pinto, C; Sabbatini, R; Santoni, M; Terrone, C; Tortora, G	1
Amdahl, J; Chandiwana, D; Delea, TE; Diaz, J; Park, J; Sharma, A	1
Choueiri, TK; Kaymakcalan, MD; Lalani, AA; Lin, X; McKay, RR; Simantov, R	1
D'Amelio, AM; Figlin, RA; Gagnon, RC; Heymach, JV; Hutson, TE; Liu, Y; Pandite, LN; Sternberg, CN; Tran, HT; Zurita, AJ	1
Akaza, H; Shibasaki, Y; Umeyama, Y	1
Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M	1
Dalhaug, A; Nieder, C; Norum, J; Pawinski, A; Syed, MA	1
Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL	1
Fujita, N; Hamano, I; Hashimoto, Y; Hatakeyama, S; Hosogoe, S; Iwamura, H; Koie, T; Kusaka, A; Ohyama, C; Tanaka, T; Tanaka, Y; Tobisawa, Y; Yamamoto, H; Yoneyama, T	1
Penel, N	1
Fife, K; Warren, A	1
Calareso, G; de Braud, F; Grassi, P; Mennitto, A; Porcu, L; Prisciandaro, M; Procopio, G; Ratta, R; Verzoni, E	1
Bahleda, R; Blanc, E; Boyle, H; Cassier, P; Chatelut, E; Escudier, B; Hollebecque, A; Metzger, S; Négrier, S; Pérol, D; Soria, JC	1
Chandramohan, J; George, AA; Georgy, JT; Mathuram, AJ	1
Asselineau, J; Aziza, R; Baud, J; Bikfalvi, A; Chauzit, E; Chevreau, C; Cornelis, F; Daste, A; Delord, JP; Digue, L; Doussau, A; Gimbert, A; Gomez-Roca, C; Molimard, M; Pedenon-Périchout, D; Picat, MQ; Quemener, C; Ravaud, A; Sitta, R	1
Gandhi, S; George, S; Jain, RK	1
Albiges, L; Derosa, L; Escudier, B; Fizazi, K; Guida, A; Loriot, Y; Massard, C	1
Aimone, P; Bao, W; Carrasco-Alfonso, MJ; Choueiri, TK; Chowdhury, S; Doehn, C; Donskov, F; Gross-Goupil, M; Haas, NB; Kopyltsov, E; Lee, JL; Lim, HY; McDermott, R; Melichar, B; Michael, A; Motzer, RJ; Reaume, MN; Rini, BI; Russo, P; Stenzl, A; Sternberg, CN; Varlamov, S; Voi, M; Wood, LA; Zemanova, M	1
Kwok, J; Patel, V; Sproat, C; Tanna, N	1
De Lobel, L; De Maeseneer, D; De Meerleer, G; De Wolf, K; Decaestecker, K; Fonteyne, V; Goetghebeur, E; Lumen, N; Ost, P; Rottey, S; Sundahl, N; Vermaelen, K	1
Kikuchi, E; Mikami, S; Mizuno, R; Oya, M; Shinojima, T; Takamatsu, K	1
Alexandre, J; Bellesoeur, A; Carton, E; Goldwasser, F; Huillard, O	1
Coen, M; Cramer, B; Serratrice, J	1
Choi, H; Gupta, S; Kang, HC; Lu, L; Matrana, MR; Tannir, NM; Wei, W	1
Ariad, S; Douvdevani, A; Dresler, H; Keizman, D; Mermershtain, W; Neulander, EZ; Riff, R; Rouvinov, K; Shani-Shrem, N	1
Figlin, RA; Leibovich, BC; Negrier, S; Stewart, GD	1
Agarwal, N; Ghate, SR; Li, N; Meiselbach, MK; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML	2
Akiyama, M; Chen, KR; Hioki, T; Makita, S; Takama, H; Watanabe, D	1
Cefalu, M; Guo, A; Ho, TH; Janssen, P; Justice, C; Kempton, A; Makara, M; Smith, SA	1
Doshi, JA; Jahnke, J; Li, P; Pettit, AR; Wong, YN	1
Beuselinck, B; Caruana, L; Couchy, G; de Reyniès, A; Job, S; Joniau, S; Laguerre, B; Lerut, E; Oyen, R; Rioux-Leclercq, N; Van Den Eynde, K; Van Poppel, H; Verbiest, A; Wozniak, A; Zucman-Rossi, J	1
'Aho, T; Armitage, JN; Eisen, T; Fife, K; Klatte, T; Matakidou, A; Riddick, AC; Sachdeva, M; Stewart, GD; Welsh, SJ	1
Hoffman-Censits, J; Mehrotra, P; Wilde, L	1
Buchler, T; Chloupkova, R; Dusek, L; Fiala, O; Finek, J; Kiss, I; Kopeckova, K; Kopecký, J; Lakomy, R; Melichar, B; Petrakova, K; Poprach, A; Slaby, O; Studentova, H; Zemanova, M	1
Basterretxea-Badiola, L; Climent, MA; Muñoz-Langa, J; Santander-Lobera, C	1
Díaz Gómez, E; García Díaz, B; Hidalgo Correas, FJ; Puebla Villaescusa, A; Ramírez Cruz, S; Salcedo Mingoarranz, ÁL	1
Bastholt, L; Bengtsen, C; Jensen, BL; Jensen, NV; Madsen, K; Tinning, AR	1
Yu-Li Su, H	1
Ball, MW; Srinivasan, R	1
Asthagiri, AR; Chen, CJ; Ilyas, A; Mehta, GU; Oldfield, EH; Schiff, D; Taylor, DG	1
Hendriks, MP; van Kalleveen, MW; Walraven, M	1
Aston, J; Chism, DD; Du, L; Koyama, T; McAlister, RK; Pollack, M	1
Rini, BI	4
Dai, Q; Dong, M; Liang, J; Peng, S; Sun, Q; Wei, N	1
Duchesneau, E; Ghate, S; McDonald, E; Messali, A; Perez, JR; Swallow, E	1
Bando, Y; Fujisawa, M; Furukawa, J; Guru, KA; Harada, K; Hinata, N; Hussein, AA; Nakano, Y; Shigemura, K; Terakawa, T	1
Foo, WC; George, DJ; Labriola, M; Zhang, T	1
Kato, Y; Miyata, T; Nakahara, J; Oya, M; Yazawa, S	1
Asai, T; Horie, S; Ichiyanagi, O; Kabasawa, T; Kato, T; Nishida, H; Sakurai, T; Tsuchiya, N; Yagi, M	1
Ahmad, QI; Ghate, S; Jiao, X; Park, J; Vogelzang, NJ; Wilson, T	1
Dietrich, M; Grünwald, V; Pond, GR	1
Botticelli, A; Calabrò, F; Caponnetto, S; Gelibter, A; Marchetti, P; Napoletano, C; Nuti, M; Rahimi, H; Rossi, E; Rughetti, A; Ruscito, I; Schinzari, G; Zizzari, IG	1
Baich, TM; Derbala, MH; Guo, AS; Ho, TH; Justice, CN; Kempton, AN; Smith, SA	1
Bodnar, L; Chrom, P; Czarnecka, AM; Kawecki, M; Stec, R; Szczylik, C	1
Cihan, YB	1
Albersen, M; Bastin, J; Bechter, O; Beuselinck, B; Clement, P; Decallonne, B; Dumez, H; Lerut, E; Oyen, R; Punie, K; Schöffski, P; Vanderschueren, D; Verbiest, A; Werbrouck, E; Wildiers, H; Woei-A-Jin, FJ; Wolter, P	1
Laguna, MP	2
Kerbel, RS; Man, S; Reguera-Nuñez, E; Xu, P	1
Ahmad, Q; Azad, A; Carrasco-Alfonso, MJ; Chang, YH; Chung, J; Davis, ID; Guo, J; Han, J; Jin, J; Lee, JL; Lim, HY; Motzer, R; Nanua, B; Oya, M; Rha, SY; Takahashi, S; Tatsugami, K; Uemura, H; Wu, HC	1
Lozano Cejudo, C; Martín-Lagos Maldonado, A; Sáenz Lozano, A	1
Basso, U; Bearz, A; Berruti, A; Bracarda, S; Buti, S; Cartenì, G; Caserta, C; Cognetti, F; Cortesi, E; De Giorgi, U; Fornarini, G; Galli, L; Giannarelli, D; Lo Re, G; Pignata, S; Porta, C; Procopio, G; Rastelli, F; Sabbatini, R; Sternberg, CN; Turci, D	1
Ciccarese, C; Iacovelli, R; Mosillo, C; Tortora, G	1
Biasco, E; Caserta, C; De Giorgi, U; Detti, B; Fornarini, G; Galli, L; Iacovelli, R; Masini, C; Morelli, F; Mosca, A; Palesandro, E; Paolieri, F; Santini, D; Sbrana, A	1
Campagna, A; Rodriguez-Pla, A; Wang, H	1
Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T	1
Chikui, K; Hirano, T; Igawa, T; Matsuo, M; Nakiri, M; Nishihara, K; Ogasawara, N; Suekane, S; Ueda, K; Uemura, K	1
Arroyo, A; Choueiri, TK; Dean, M; Escudier, B; Geertsen, PF; George, D; Grande, E; Gross-Goupil, M; Gurney, H; Kollmannsberger, C; Markby, DW; Motzer, RJ; Pal, S; Park, SH; Pikiel, J; Powles, T; Rha, SY; Suarez, C	1
Bastos, DA; Bonadio, RRCC; Dzik, C; Isaacsson Velho, P; Marta, GN; Muniz, DQB; Nardo, M; Souza, MCLA	1
Bellmunt, J; Bossé, D; Choueiri, TK; Harshman, LC; Jacobus, S; Lalani, AA; Lundgren, K; Moreno, I; Polacek, L; Rosenberg, JE; Takeda, DY; Van Allen, EM; Wagle, N; Wankowicz, SA	1
Basappa, N; Bjarnason, GAG; Dragomir, A; Heng, D; Jewett, M; Kapoor, A; Kollmannsberger, C; Lévesque, E; Nazha, S; Reaume, MN; Soulières, D; Tanguay, S; Wood, L	1
Basso, U; Berardi, R; Bersanelli, M; Burattini, L; Buti, S; Conti, A; De Giorgi, U; Iuliani, M; Lolli, C; Maruzzo, M; Mazzucchelli, R; Montironi, R; Mosca, A; Piva, F; Santini, D; Santoni, M; Terrone, C	1
Albiges, L; Barthélémy, P; Bouleftour, W; Chevreau, C; Culine, S; Espenel, S; Fizazi, K; Gravis, G; Guillot, A; Houede, N; Joly, C; Mahammedi, H; Meriaux, E; Negrier, S; Oriol, M; Pouessel, D; Roubaud, G; Tartas, S; Tinquaut, F; Vassal, C	1
Amin, A; Bauer, TM; Berghorn, E; Carducci, M; Ernstoff, MS; Hammers, HJ; Heng, DYC; Knox, J; Kollmannsberger, C; Lewis, LD; McDermott, DF; Plimack, ER; Rini, BI; Spratlin, J; Voss, MH; Yang, L	1
Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gavalas, N; Gkerzelis, I; Karavasilis, V; Kostouros, E; Koutras, A; Koutsoukos, K; Samantas, E; Tzannis, K; Zagouri, F	1
Alva, AS; Daignault-Newton, S; Dedinsky, R; Felton, JA; Gersch, C; Karsies, D; Kraft, S; Rae, JM; Redman, BG; Reimers, MA; Riddle, L; Shango, MM; Wen, B	1
Fujisawa, M; Hinata, N; Jimbo, N; Shigemura, K; Shiraishi, Y; Terakawa, T	1
Chien, CR; Geynisman, DM; Kim, B; Shih, YT; Xu, Y	1
Anido, U; Chirivella, I; Etxaniz, O; Fernández-Parra, E; Gallardo, E; Guix, M; Hernández, C; Lambea, J; Méndez-Vidal, MJ; Molina, Á; Montesa, Á; Pinto, Á; Ros, S	1
Ravaud, A	1
Bedke, J; Beeker, A; Bögemann, M; Bokemeyer, C; Bolenz, C; De Santis, M; Frank, M; Grimm, MO; Gschwend, JE; Indorf, M; Lehmann, J; Leiber, C; Müller, L; Retz, M; Teber, D; van Alphen, R; Wirth, M; Zimmermann, U	1
Bae, WK; Byun, SS; Chung, HS; Chung, J; Hong, SH; Hwang, EC; Hwang, JE; Jeong, CW; Jung, SI; Kim, MS; Kwak, C; Kwon, DD; Park, JY; Seo, SI; Song, C	1
Jensen, E; Maganti, K; Raiker, NK; Wodzinski, B	1
Borchiellini, D	1
Hira, D; Ikeda, Y; Kageyama, S; Kawauchi, A; Morita, SY; Murai, R; Noda, S; Terada, T; Tomita, K; Tsuru, T; Yoshida, T	1
Albiges, L; Auclin, E; Auvray, M; Barthelemy, P; Bono, P; De Velasco, G; Escudier, B; Gravis, G; Gross-Goupil, M; Kellokumpu-Lehtinen, P; Mouillet, G; Mourey, L; Powles, T; Priou, F; Rolland, F; Vano, YA	1
Çiçin, İ; Demircan, NC; Erdoğan, B; Gökyer, A; Hacıoğlu, MB; Köstek, O; Tunçbilek, N; Uzunoğlu, S; Yılmaz, E	1
Kaneko, G; Kondo, H; Makabe, H; Nishimoto, K; Okabe, T; Oyama, M; Shirotake, S; Todo, M; Yasumizu, Y	1
Anota, A; Berthod, D; Bonnetain, F; Es-Saad, I; Fritzsch, J; Meurisse, A; Mouillet, G; Mouyabi, K; Paget-Bailly, S; Pozet, A; Thiery-Vuillemin, A; Vernerey, D	1
Fujisawa, M; Furukawa, J; Harada, K; Hinata, N; Inoue, T; Nakamura, I; Nakano, Y; Ogawa, T; Okamura, Y; Terakawa, T	1
Ahmad, Q; Bamias, A; Bono, P; Dezzani, L; Hawkins, R; Hirschberg, Y; Jonasch, E; Kalofonos, H; Pisal, CB; Procopio, G; Sanchez, AR; Schmidinger, M; Srihari, N; Vázquez, S	1
Chen, S; Gong, P; Huang, C; Lowerison, MR; Lucien, F; Song, P; Wang, D	1
Fukuda, H; Iizuka, J; Ishida, H; Ishihara, H; Kobayashi, H; Kondo, T; Okumi, M; Takagi, T; Tanabe, K; Yoshida, K	1
Milhem, M; Stein, J; Vaena, D	1
Skubitz, KM	1
Abbas, H; Alam, T; Faust, G; Nair, A; Paskins, J; Uccello, M	1
Cozar Olmo, JM; Exposito Ruiz, M; Hernández Hernández, C; Varilla-Varilla, C; Vázquez Alonso, F	1
Donskov, F; Fristrup, N	1
Cao, Z; Deng, H; Hong, Z; Huang, Y; Wei, Y; Yuan, X; Zhang, W	1
Li, J; Qi, G; Wang, Q; Wu, G; Xia, Q; Xu, Y; Zhang, H	1
Ahmad, Q; Bamias, A; Bono, P; Dezzani, L; Estevez, SV; Hawkins, R; Hirschberg, Y; Jonasch, E; Kalofonos, H; Pisal, CB; Procopio, G; Rodriguez, CS; Sánchez, AR; Schmidinger, M; Srihari, N	1
Albersen, M; Albigès, L; Beuselinck, B; Caruso, S; Couchy, G; Elaidi, RT; Fridman, WH; Job, S; Laenen, A; Lerut, E; Oudard, S; Renders, I; Rioux-Leclercq, N; Sautès-Fridman, C; Schöffski, P; Vano, Y; Verbiest, A; Verkarre, V; Wozniak, A; Zucman-Rossi, J	1
Bauernhofer, T; Gerritsmann, H; Kratochvill, F; Kretz, M; Loidl, W; Marszalek, M; Mitterberger, M; Mraz, B; Niedersüß-Beke, D; Pfleger, G; Pichler, R; Schmidinger, M; Stöger, H; Tinchon, C; Tulchiner, G; Vogl, U; Wiesinger, CG	1
Chandramohan, A; Corn, PG; Devine, CE; Gonzalez, GMN; Karam, JA; Lim, ZD; Msaouel, P; Pruitt, L; Ross, JA; Tannir, NM; Wang, J; Wang, X; Wood, CG; Zurita, AJ	1
Altavilla, A; Attademo, L; De Giorgi, U; De Lisi, D; Pignata, S; Procopio, G; Santini, D; Verzoni, E	1
Domike, R; Gurumurthi, K; Kluetz, P; Pazdur, R; Raju, GK; Singh, H; Weinstock, C; Woodcock, J	1
Bagrodia, A; Bowman, I; Brugarolas, J; Choy, H; Christie, A; Courtney, K; Desai, N; Garant, A; Hammers, H; Hannan, R; Margulis, V; Mohamad, O; Schoenhals, J; Singla, N; Timmerman, R; Wang, C; Zhang, Y	1
Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E	1
Dutcher, JP; Garrett, M; Kim, S; Motzer, RJ; Pithavala, YK; Poland, B; Rini, BI; Rixe, O; Stadler, WM; Tarazi, J; Wilding, G	1
Bhattacharyya, H; Cella, D; Chen, C; Escudier, B; Kim, S; Motzer, R; Rini, B; Rosbrook, B; Tarazi, J	1
Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Jones, R; Kayani, I; Lim, L; Peters, J; Powles, T; Reynolds, AR; Sahdev, A; Shamash, J; Sharpe, K; Stewart, GD	1
Bex, A	1
Chen, C; Escudier, B; Gore, ME; Hariharan, S; Hutson, TE; Kim, S; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Rini, BI; Rosbrook, B; Tarazi, J; Tomczak, P	1
Büchler, T; Finek, J; Hájek, J; Kocák, I; Kubácková, K; Lakomý, R; Melichar, B; Petruzelka, L; Poprach, A; Siffnerová, M; Tomásek, J; Vyzula, R; Zemanová, M	1
Marchesi, V	1
Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H	1
Caulfield, TR; Cooper, SJ; Copland, JA; Marlow, LA; Tan, WW; Tun, HW; von Roemeling, CA; Wei, JJ; Wu, K	1
Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T	1
Payton, S	2
Arrowsmith, ER; Crane, EJ; Franco, LA; Hainsworth, JD; Khatcheressian, J; Rubin, MS	1
Kai, F; Nagata, M; Ozono, S; Sugiyama, T; Takayama, T	1
Bonate, PL; Suttle, AB	1
Bono, P; Joensuu, H; Peltola, K; Rautiola, J; Utriainen, T	1
De Tursi, M; Felici, A; Lo Re, G; Milella, M; Ricotta, R; Ruggeri, EM; Sabbatini, R; Santini, D; Santoni, M; Vaccaro, V	1
Atkinson, BJ; Charnsangave, C; Corn, P; Duran, C; Jonasch, E; Matrana, MR; Millikan, RE; Pagliaro, LC; Shetty, A; Tannir, NM; Xiao, L	1
Bahamon, B; Baker-Neblett, KL; Brown, V; Carpenter, C; Choueiri, TK; Fay, AP; Gagnon, R; Hutson, TE; Lin, Y; Liu, Y; Pandite, L; Rosenberg, JE; Signoretti, S	1
Soulières, D	1
Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS	1
Füessl, HS; Stiefelhagen, P	1
Boleti, E; Cella, D; Choueiri, TK; Crescenzo, R; De Giorgi, U; de Souza, P; Deen, K; Fife, K; Guo, J; Hackshaw, MD; Harmenberg, U; Hawkins, R; Hutson, TE; Jin, J; Jones, R; McCann, L; Merchan, JR; Motzer, RJ; Nathan, P; Pandite, LN; Reeves, J; Staehler, M; Sternberg, CN; Uemura, H; Wang, J	1
Heng, DY; Molina, AM; Motzer, RJ	1
Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C	1
Hernández-Pastor, LJ; Villa, G	1
Broom, RJ; Dranitsaris, G; Schmitz, S	1
Alesini, D; Cascinu, S; Cortesi, E; De Marchis, L; Iacovelli, R; Naso, G; Palazzo, A; Santoni, M; Trenta, P	1
Bodoky, G; Bodrogi, I; Csejtei, A; Dank, M; Géczi, L; Küronya, Z; Mangel, L; Maráz, A; Petrányi, A; Szûcs, M	1
Linehan, WM; Srinivasan, R	1
Albiges, L; Ammari, S; Benmoussa, L; Escudier, B; Levy, A	1
Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY	1
Buti, S; Porta, C	1
Andrews, GI; Arranz, JA; Bair, AH; Fishman, MN; Grünwald, V; Jonasch, E; Kim, S; Melichar, B; Pavlov, D; Pithavala, YK; Rini, BI; Ueda, T	1
Azad, A; Maddison, C; Stewart, J	1
Larkin, J; Yousaf, N	1
Al-Shukri, S; Bair, AH; Chen, C; Hutson, TE; Kim, S; Lesovoy, V; Lipatov, ON; Rosbrook, B; Stus, VP; Vogelzang, NJ	1
Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Okamoto, A; Yamamoto, H; Yoneyama, T	1
Afsar, B; Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Deger, SM; Gonul, II; Gumusay, O; Ozet, A	1
Akaza, H; Fukuyama, T	1
Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T	1
Khenifer, S; Pasquet, F; Pavic, M; Péron, J; Potier, V; Rassat, R; Vitry, T	1
Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L	1
Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E	1
De Braud, FM; Iacovelli, R; Procopio, G; Verzoni, E	1
Ahrar, K; Devine, CE; Karam, JA; Lozano, M; Maity, T; Tamboli, P; Tannir, NM; Urbauer, DL; Wood, CG	1
Atkinson, BJ; Flaherty, AL; Jonasch, E; Matrana, MR; Shetty, AV; Tannir, NM	1
Funahashi, Y; Gotoh, M; Inoue, S; Kato, M; Maeda, M; Sassa, N	1
Bellmunt, J; Calvo, E; Grünwald, V	1
Arruda, LS; Baum, M; Cisar, L; Kim, S; Motzer, RJ; Quinn, DI; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J; Wood, LS	1
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R	1
Galsky, MD; Leiter, A	1
Bracarda, S; Castellano, D; Procopio, G; Schmidinger, M; Sepúlveda, JM; Sisani, M; Verzoni, E	1
Broom, RJ; Hadden, P; Jebb, A	1
Miyajima, A; Mizuno, R; Oya, M	1
Bono, P; Cella, D; De Giorgi, U; Diaz, J; Eisen, T; Escudier, B; Gschwend, JE; Hawkins, R; Khan, S; Mehmud, F; Négrier, S; Parikh, O; Porta, C; Powles, T; Redhu, S; Sevin, E; Sternberg, CN	1
Garnick, MB	1
Blanc, E; Cassier, P; Chatelut, E; Escudier, B; Hollebecque, A; Imbs, DC; Lafont, T; Négrier, S; Pérol, D; Soria, JC; Varga, A	1
Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D	1
Rexer, H	3
Figlin, RA; Posadas, EM	1
Wada, Y	1
Choueiri, TK; Deen, K; Hutson, TE; McCann, L; Motzer, RJ	1
Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN	1
Cisar, L; Clark, JI; Escudier, B; Hariharan, S; Hutson, TE; Kannourakis, G; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Porfiri, E; Rini, BI; Rosbrook, B; Staehler, M; Tarazi, J; Zalewski, P	1
Hackshaw, MD; Miller, LA; Nagar, SP; Parks, DC	1
Schmidinger, M	1
Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P	1
Bozcuk, H; Coskun, HS; Gunduz, S; Mutlu, H; Uysal, M	1
Elkord, E; Gilham, DE; Hawkins, RE; Shablak, A	1
Beato-Merino, M; Casado-Verrier, B; Delgado-Mucientes, C; Pérez-Santos, S	1
McCormack, PL	1
Arruda, LS; Borst, DL; MacLean, E; Morgado, JE; Pithavala, YK	1
Bay, JO; Brotelle, T	1
Cho, YC; Jang, BC; Jang, JH; Kim, DE; Kim, KH; Kim, S; Kwon, TK; Lee, J; Lee, KS; Park, JS; Park, JW	1
Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E	1
Bernal-Becerra, I; Cabezas-Camarero, S; Corona, JA; Díaz-Rubio, E; González-Larriba, JL; Manzano, A; Puente, J; Sotelo, M	1
Cai, P; Gu, Y; Li, Q; Sun, Y; Wang, W; Xu, Q; Yuan, H	1
Acharyya, S; Chopra, A; Fay, AP; Haaland, B; Lopes, Gde L	1
Hasegawa, T; Hashimoto, A; Hayashi, T; Hirayama, Y; Horiguchi, H; Iyama, S; Kato, J; Kitamura, H; Kobune, M; Masumori, N; Miyanishi, K; Murase, K; Nakanishi, K; Ono, K; Sato, T; Sato, Y; Takada, K; Takimoto, R; Tatekoshi, A	1
Bourlon, MT; Kessler, ER	1
Davis, ID; Deen, KC; Hawkins, RE; Sigal, E; Sternberg, CN	1
Akaza, H; Eto, M; Fujii, Y; Kamei, Y; Kanayama, H; Naito, S; Ozono, S; Shinohara, N; Tomita, Y; Uemura, H; Umeyama, Y	1
Carmichael, C; Frankel, PH; Hossain, DM; Jones, JO; Kortylewski, M; Lau, C; Pal, SK; Ruel, C; Zhang, Q	1
Nishiyama, T; Niwa, N; Ozu, C; Saito, S; Yagi, Y	1
Bair, AH; Chen, Y; Mugundu, GM; Pithavala, YK; Rini, BI	1
Amado, R; Ball, HA; Carpenter, C; Hutson, TE; Lin, Y; Molimard, M; Pandite, L; Rajagopalan, D; Suttle, AB; Swann, S	1
Albiges, L; Boyle, H; Ederhy, S; Escudier, B; Gravis, G; Hartl, D; Izzedine, H; Robert, C; Scotté, F	1
Adelaiye, R; Barrera, G; Ciamporcero, E; Ku, S; Miles, KM; Pili, R; Pizzimenti, S; Ramakrishnan, S; Sennino, B; Shen, L	1
Bing, N; Cardon, LR; Cheng, YC; Cox, NJ; Das, S; Gamazon, ER; Karrison, TG; Kistner-Griffin, E; Levine, MR; Liu, Y; Maitland, ML; Mitchell, BD; O'Connell, JR; Pandite, LN; Ratain, MJ; Ryan, KA; Shuldiner, AR; Thomeas, V; Torgerson, D; Wilson, PA; Xu, CF	1
Fujisawa, M; Harada, K; Imai, S; Miyake, H; Miyazaki, A	1
Albiges, L; Escudier, B; Fizazi, K; Iacovelli, R; Loriot, Y; Massard, C; Massari, F	1
Bhowmik, D; Hackshaw, MD; Hutson, TE; Jonasch, E; Rembert, D; Vogelzang, NJ; Yap, M	1
Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P	1
Atkinson, BJ; Cauley, DH; Chen, AH; Land, JD; Tannir, NM	1
Benson, P; Carpenter, C; Choueiri, TK; de Souza, P; Deen, K; Fay, AP; Figueroa, DJ; Gagnon, R; Ho, TH; Liu, Y; Motzer, RJ; Pandite, L; Powles, T; Signoretti, S	1
Arondekar, B; Deen, KC; Hackshaw, MD; Hansen, RN; Nagar, SP; Ramsey, SD; Sullivan, SD	1
Amdahl, J; Delea, TE; Diaz, J; Hackshaw, MD; Nakhaipour, HR	1
Ito, T; Kutikov, A	1
Hamada, A; Inoue, T; Kamba, T; Kobayashi, T; Matsui, Y; Negoro, H; Ogawa, O; Sugino, Y; Terada, N; Yamasaki, T; Yoshimura, K	1
He, CS; Huang, JK; Lin, QZ; Xie, M	1
Chen, J; Cronin, CN; Johnson, E; Kallioniemi, O; Kontro, M; McTigue, M; Murray, BW; Pemovska, T; Porkka, K; Repasky, GA; Wells, P; Wennerberg, K	1
Agarwal, N; Beard, C; Bhayani, S; Bolger, GB; Chang, SS; Choueiri, TK; Costello, BA; Derweesh, IH; Dwyer, M; Gupta, S; Hancock, SL; Jonasch, E; Kim, JJ; Kumar, R; Kuzel, TM; Lam, ET; Lau, C; Levine, EG; Lin, DW; Michaelson, MD; Motzer, RJ; Olencki, T; Pili, R; Plimack, ER; Rampersaud, EN; Redman, BG; Ryan, CJ; Sheinfeld, J; Shuch, B; Sircar, K; Somer, B; Wilder, RB	1
Bing, N; Choueiri, TK; Davis, ID; Deen, KC; Esteban, E; Garcia-Donas, J; Johnson, T; McCann, L; Motzer, RJ; Pandite, LN; Rodríguez-Antona, C; Spraggs, CF; Sternberg, CN; Whittaker, JC; Xu, CF; Xue, Z	1
Bair, AH; Chen, Y; Fishman, MN; Grünwald, V; Melichar, B; Oya, M; Pithavala, YK; Rini, BI	1
Han, S; Hyun, C; Jo, J; Kim, JH; Kim, JY; Kim, W; Kwon, J; Rhee, J	1
Abrishami, P; Bucsics, A; Di Bidino, R; Goettsch, WG; Happonen, P; Kleijnen, S; Montilla, S; Muscolo, LA; Pasternack, I; Pulis, IZ; Rannanheimo, P; Sacchini, D; Sammut, SM; Van de Casteele, M; Vuola, JM	1
Climent-Durán, MÁ; Iborra, I; Ramírez-Backhaus, M; Rubio-Briones, J; Solsona-Narbón, E; Valverde-Martínez, S	1
Campbell, SC; Chen, DY; Dreicer, R; Elson, P; Fergany, A; Garcia, J; Gilligan, T; Kaouk, J; Klein, EA; Krishnamurthi, V; Plimack, ER; Rini, BI; Stephenson, AJ; Takagi, T; Uzzo, RG; Wood, LS; Zhang, Z	1
English, PA; Escudier, B; Huang, X; Kim, S; Loomis, AK; Motzer, RJ; Rini, BI; Rosbrook, B; Tarazi, J; Williams, JA	1
Fife, K; Welsh, SJ	1
Qin, S; Zhang, S	1
Bjarnason, GA; Bocci, G; Di Desidero, T; Jedeszko, C; Kerbel, RS; Lee, CR; Man, S; Paez-Ribes, M; Xu, P	1
Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Mori, K; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T	1
Abarzúa, Á; Giesen, L; González, S; Molgó, M	1
Albiges, L; Carton, E; Escudier, B; Gizzi, M	1
Abdallah, AO; Kunthur, A; Vallurupalli, S	1
Petrou, P	1
Burton, TM; Byfield, SA; Hackshaw, MD; McPheeters, JT; Nagar, SP	1
Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P	1
Atkinson, BJ; Corn, PG; Jonasch, E; Kalra, S; Karam, JA; Matin, SF; Matrana, MR; Rao, P; Sircar, K; Tamboli, P; Tannir, NM; Wood, CG	1
Abel, EJ; Allaf, ME; Bex, A; Devine, CE; Fellman, BM; Karam, JA; Lane, BR; Thompson, RH; Urbauer, DL; Wood, CG	1
Rixe, O; Zakharia, K; Zakharia, Y	1
Brossart, P; Daecke, SN; Flores, C; Heine, A; Held, SA; Kotthoff, P; Kurts, C; Riethausen, K	1
Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T	1
Behzadigohar, R; Rosenthal, MA; Tran, B	1
Armand, JP; Dumont, S; Mir, O	1
Bhatt, K; Kattan, MW; McCann, L; Mehmud, F; Motzer, RJ; Sternberg, CN	1
Bex, A; Blank, CU; Broeks, A; de Gruijl, TD; Gadiot, J; Guislain, A; Haanen, JB; Jordanova, ES; Kaiser, A; Sanders, J; van Boven, H	1
Schmidinger, M; Wittes, J	1
Greco, F; Mirone, V	1
Huang, J; Shan, L; Song, Y; Zhang, HT	1
Dahmani, B; De Boer, A; Fathallah, M; Goettsch, WG; Kleijnen, S; Leufkens, HG; Timoney, A; van der Linden, MW; Vancraeynest, P	1
Fukuhara, H; Kato, T; Kawazoe, H; Nishida, H; Sakurai, T; Shibasaki, T; Tomita, Y; Yamagishi, A	1
Askerova, Z; DeAnnuntis, LL; Escudier, B; Hariharan, S; Motzer, RJ; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J	1
Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS	1
Tomita, Y	1
Racsa, PN; Whisman, TR; Worley, K	1
Fujisawa, M; Harada, K; Imai, S; Miyake, H	1
Chen, Y; Dutcher, JP; Garrett, M; Motzer, RJ; Pithavala, YK; Rini, BI; Rixe, O; Stadler, WM; Tarazi, J; Wilding, G	1
Beaumont, JL; Cella, D; Diaz, J; Khan, S; Lai, JS	1
Amantini, C; Cardinali, C; Morelli, MB; Nabissi, M; Santoni, A; Santoni, G; Santoni, M; Soriani, A	1
Burge, F; Sundar, S	1
Bahl, A; Brown, J; Buchan, S; Hawkins, R; Jones, R; Pickering, L; Porfiri, E; Wagstaff, J	1
Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W	1
Grünwald, V; Ivanyi, P	1
Atkinson, B; Bathala, T; Campbell, MT; Corn, P; Duran, C; Jonasch, E; Kalra, S; Matrana, MR; Shetty, A; Tannir, NM; Teegavarapu, P; Xiao, L	1
Izumi, K; Konaka, H; Mizokami, A; Namiki, M; Yaegashi, H	1
Fujisawa, M; Miyake, H; Miyazaki, A	1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ	1
Kichenadasse, G; Mangoni, AA; Rowland, A; Sorich, MJ; Woodman, RJ	2
Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D	1
Adomi, S; Minami, T; Nose, K; Nozawa, M; Ohzeki, T; Saito, Y; Shimizu, N; Sugimoto, K; Uemura, H; Yoshimura, K	1
Carpenter, C; Figlin, RA; Goldstein, D; McCann, L; Pandite, L; Rosenberg, JE; Townsend, RR	1
Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ	1
Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A	1
Daido, Y; Kitamura, Y; Nishimoto, K; Shinchi, Y; Takao, M; Tokonabe, S; Yoshii, H	1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C	1
Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M	1
Bersanelli, M; Buti, S; Facchinetti, F; Maiorana, M; Tiseo, M	1
Griswold, J; Parekh, H; Rini, B	1
Granovetter, M	1
Gooch, ME; Kubicek, GJ; Nader, K; Somer, RA	1
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S	1
Delea, TE; Diaz, J; Latimer, N; Mehmud, F; Motzer, RJ; Pandite, L; Sternberg, CN	1
Epskamp, C; Hamberg, P; Snels, DG; Yo, GL; Zuetenhorst, HJ	1
Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C	1
Beaumont, JL; Cella, D; Deen, KC; Diaz, J; Hackshaw, MD; McCann, L; Motzer, RJ; Powles, T; Salsman, JM	1
Borgel, S; Bottaro, DP; Doroshow, JH; Evrard, YA; Hollingshead, MG; Ji, JJ; Khin, SA; Kinders, RJ; Linehan, WM; Navas, T; Parchment, RE; Pfister, TD; Srivastava, AK; Tomaszewski, JE; Weiner, J; Zhang, Y	1
Kononenko, OA; Stakhovskiy, EO; Stakhovskiy, OE; Vitruk, YV; Voylenko, OA; Vukalovych, PS	1
Bergmann, L; Maute, L	1
Hira, D; Jo, F; Kageyama, S; Kawauchi, A; Morita, SY; Noda, S; Terada, T; Wada, A; Yoshida, T	1
Keck, B; Lieb, V; Lüdecke, G; Sikic, D	1
Kondakova, IV; Slonimskaya, EM; Spirina, LV; Usynin, EA; Yurmazov, ZA	1
Andrikou, K; Bianconi, M; Bittoni, A; Burattini, L; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Montironi, R; Scartozzi, M; Zizzi, A	1
Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Quivy, A; Ravaud, A	1
Eaddy, M; Hackshaw, MD; Holmes, M; Lankford, M; Ogbonnaya, A; Thomas, M	1
Cisar, L; Eremina, D; MacLean, E; Mehle, K; Quigley, JM	1
Andrews, GI; Bair, AH; Fishman, MN; Grünwald, V; Jonasch, E; Melichar, B; Oya, M; Rini, BI; Rosbrook, B; Tomita, Y; Ueda, T; Uemura, H	1
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R	1
Goto, H; Kiyohara, Y; Niwakawa, M; Omodaka, T; Otsuka, M; Yoshikawa, S; Yoshimi, K	1
Alimzhanov, M; Alsop, DC; Atkins, MB; Bhasin, MK; Bhatt, RS; Callea, M; Khanna, P; Kumar, R; Mier, JW; Pearsall, RS; Signoretti, S; Solban, N; Song, J; Wang, X	1
Ackerman, C; Aitchison, M; Beltran, L; Boleti, E; Chowdhury, S; Crabb, S; Harvey-Jones, E; Jones, R; Michel, C; O'Brien, T; Oades, G; Peters, J; Powles, T; Protheroe, A; Sahdev, A; Sarker, SJ; Sarwar, N; Smith, K; Stockdale, A; Sullivan, M; Trevisan, G; Wimalasingham, A; Worth, D	1
De Groot, S; Haanen, JB; Kiemeney, LA; Oosterwijk, E; Redekop, WK; Sleijfer, S; Uyl-de Groot, CA	1
Abe, H; Arai, K; Fukuda, T; Kamai, T; Masuda, A; Nukui, A; Yoshida, K	1
Fujisaki, A; Komatsubara, M; Kurokawa, S; Morita, T; Yamazaki, M	1
Annala, M; Azad, AA; Chi, KN; Fazli, L; Mo, F; Nappi, L; Wyatt, AW	1
Kim, JH; Lee, JL; Park, I	1
Kok, VC; Kuo, JT	1
Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, J; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, M	1
Fujisawa, M; Harada, K; Miyake, H; Ozono, S	1
Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J	1
Fujisawa, M; Harada, KI; Miyake, H; Ozono, S	1
Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK	1
Kim, MJ; Lee, JL; Lee, SH; Lee, SJ; Lim, HY; Park, SH	1
Beuselinck, B; Bjarnason, GA; Choueiri, TK; Donskov, F; Fraccon, AP; Heng, DY; Lee, JL; Pasini, F; Pezaro, C; Ptak-Chmielewska, A; Rini, BI; Ruiz-Morales, JM; Sim, HW; Sliwczynsk, A; Swierkowski, M; Szczylik, C; Teter, Z; Wells, JC; Wood, LA; Yuasa, T	1
Eisen, T; Escudier, B; Grünwald, V; Larkin, J; McDermott, D; Oldenburg, J; Porta, C; Putora, PM; Rini, B; Rothermundt, C; Schmidinger, M; Sternberg, CN; von Rappard, J	1
Al-Shukri, S; Andrews, GI; Bair, AH; Hutson, TE; Lipatov, ON; Rosbrook, B; Shparyk, Y; Stus, VP; Vogelzang, NJ	1
Bieche, I; Bousquet, G; Bryan, BA; de Gramont, A; Dos Santos, C; Faivre, S; Gapihan, G; Janin, A; Lopez, A; Martinet, M; Mitchell, DC; Neuzillet, C; Raymond, E; Riveiro, ME; Serova, M; Tijeras-Raballand, A	1
Golčić, M; Petković, M	1
Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T	1
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Goldwasser, F; Huillard, O; Jouinot, A; Thomas-Schoemann, A; Tlemsani, C; Vidal, M	1
Alamri, S; Atkinson, B; Baiomy, A; Campbell, M; Corn, P; Elsayes, KM; Jonasch, E; Kalra, S; Matrana, MR; Shetty, A; Tannir, NM; Teegavarapu, P; Xiao, L	1
Asai, M; Gotoh, M; Iwai, A; Kato, H; Miyazaki, M; Noda, Y; Sassa, N; Takeuchi, M; Yamada, K	1
Maltezou, M; Miaris, N; Papaxoinis, G; Samantas, E; Visvikis, A	1
Campanario, R; Juárez, A; Saiz, R; Soto, M	1
Allman, K; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Martin, A; Ornstein, MC; Rini, BI; Wood, L	1
Fishkin, P; Karczmar, GS; Karrison, T; Medved, M; O'Donnell, PH; Oto, A; Stadler, WM; Sweis, RF; Szmulewitz, RZ; Towey, S	1
Chi, Y; Cui, CX; Du, CX; Song, Y; Sun, Y; Sun, YK; Wang, JW; Yang, L; Zhang, W; Zhou, AP	1
Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M	1
Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolè, F; Verri, E	1
Arai, Y; Asano, T; Isono, M; Ito, K; Koga, A; Masunaga, A; Shinchi, Y; Tachi, K	1
Aarts, MJ; Beerepoot, LV; Cirkel, GA; Dercksen, MW; Groenewegen, G; Haanen, JBAG; Hamberg, P; Klümpen, HJ; Lolkema, MP; Loosveld, OJL; Los, M; Peters, FPJ; Polee, MB; Portielje, JEA; Sleijfer, S; Tascilar, M; van den Berkmortel, F; van der Noort, V; Voest, EE	1
Hatano, K; Ishizuya, Y; Kakimoto, KI; Nakai, Y; Nakayama, M; Nishimura, K; Okusa, T	1
Bedke, J; Stühler, V	1
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A	1
Abdulfatah, E; Kukreja, G; Nagasaka, M; Sukari, A; Vaishampayan, U	1
Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C	1
Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A	1
Bono, P; Peltola, K; Penttilä, P; Poussa, T; Rautiola, J	1
Bersanelli, M; Buti, S; Caffo, O; De Giorgi, U; Facchini, G; Fornarini, G; Fraccon, AP; Gelsomino, F; Leonardi, F; Librici, C; Maines, F; Maruzzo, M; Masini, C; Morelli, F; Prati, G; Santoni, M; Sava, T; Verri, E; Vitale, MG; Zustovich, F	1
Agarwal, N; Ghate, SR; Li, N; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML	1
Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R	1
Capri, S; Delea, TE; Porta, C	1
Abdel-Rahman, O; Elhalawani, H; Heiba, M	1
Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H	1
Aggarwal, R; Bartelink, I; Cripps, A; Grabowsky, J; Harb, A; Jahan, T; Leng, J; Mastroserio, I; Munster, PN; Pawlowska, N; Reinert, A; Ryan, CJ; Thomas, S; Truong, TG	1
Iwamura, M; Koguchi, D; Minamida, S; Shimura, S; Taoka, Y	1
Ghate, SR; Li, N; Liu, Z; Pal, SK; Perez, JR; Signorovitch, JE; Vogelzang, NJ; Zichlin, ML	1
Stone, L	1
Bair, AH; Fujii, Y; Fukasawa, S; Habuchi, T; Kamei, Y; Oya, M; Rini, BI; Shinohara, N; Tomita, Y; Uemura, H; Umeyama, Y	1
Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M	1
Bushmakin, AG; Bycott, P; Cappelleri, JC; Kim, S; Liau, K; Trask, PC	1
Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M	1
Bukowski, RM; Vakkalanka, BK	1
Alexandre, I; Billemont, B; Meric, JB; Richard, S; Rixe, O	1
Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B	1
Dutcher, JP; Hudes, G; Kim, S; Rini, BI; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC; Wilding, G; Wood, L	1
Cella, D	1
Limvorasak, S; Posadas, EM	1
Hutson, TE; Sonpavde, G; Sternberg, CN	2
Baker, KL; Crofts, T; Davis, ID; De Souza, PL; Epstein, RJ; Figlin, RA; Hong, BF; Hutson, TE; Machiels, JP; McCann, L; Pandite, L; Rottey, S	1
Bukowski, RM; Kirkpatrick, P; Yasothan, U	1
Barrios, CH; Chen, M; Davis, ID; Gladkov, OA; Hawkins, RE; Kavina, A; Lee, E; Mardiak, J; McCann, L; Pandite, L; Roychowdhury, DF; Salman, P; Sternberg, CN; Szczylik, C; Wagstaff, J; Zarbá, JJ	1
Choueiri, TK	1
Baker, KL; Cardon, LR; Chen, EP; Chen, M; Ellens, HE; Huang, L; Mooser, VE; Pandite, L; Reck, BH; Spraggs, CF; Xu, CF; Xue, Z	1
LaPlant, KD; Louzon, PD	1
Bukowski, RM	1
Sternberg, CN	1
Jeldres, C; Karakiewicz, PI; Perrotte, P; Sun, M	1
Figlin, RA; Pal, SK	2
Keating, GM; Sanford, M	1
Gore, M; Larkin, J	1
Goldstein, R; Larkin, J; Pickering, L	1
Stadler, WM; Ward, JE	1
Biglietto, M; Buonerba, C; Cartenì, G; Chiurazzi, B; Di Lorenzo, G; Riccardi, F; Scognamiglio, F	1
Barnes, MR; Cardon, LR; Goodman, VL; Huang, L; Koshy, B; Mooser, VE; Pandite, LN; Reck, BH; Spraggs, CF; Xu, CF; Xue, Z	1
Biró, K; Küronya, Z	1
Keisner, SV; Shah, SR	1
Maráz, A	1
Al-Marrawi, MY; Rini, B	1
Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R	1
Griffiths, C; Hay, N; Stevens, A; Sutcliffe, F	1
Ball, HA; Bing, NX; Cardon, LR; de Souza, P; Hutson, TE; King, KS; McCann, L; Mooser, VE; Pandite, LN; Ragone, LJ; Rajagopalan, D; Spraggs, CF; Sternberg, CN; Whittaker, JC; Xu, CF; Xue, ZG	1
Antràs, L; Cella, D; Duh, MS; Guerin, A; Hodge, R; McCann, L; Mishagina, N; Neary, MP; Pickard, AS; Sternberg, CN	1
Chan, AL; Leung, HW	1
Bergmann, L; Gschwend, J; Keilholz, U; Miller, K	1
Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C	1
Pal, SK; Vogelzang, NJ	2
Lim, ZD; Matrana, MR; Ng, C; Rao, P; Tannir, NM	1
Canter, D; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Uzzo, RG	1
Akaza, H; Fujimoto, H; Imai, K; Kanayama, HO; Naito, S; Nakazawa, H; Ozono, S; Shinohara, N; Tomita, Y; Uemura, H; Umeyama, Y	1
Joly, F	1
Bourdeanu, L; Pal, SK; Twardowski, P	1
Grünberger, B	1
Abadie, E; Borregaard, J; Ersbøll, J; Nieto, M; Pignatti, F; Schellens, JH; ten Bosch, GJ; van Zwieten-Boot, B	1
Ho, TH; Jonasch, E	1
Bex, A; Haanen, J	1
Castellano, D; Cella, D; Chen, C; Escudier, B; Gorbunova, VA; Gore, ME; Hutson, TE; Kaprin, A; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Negrier, S; Ou, YC; Rini, BI; Rosbrook, B; Rusakov, IG; Szczylik, C; Tarazi, J; Tomczak, P; Uemura, H	1
Appleman, LJ; Carlson, DM; Chen, J; Cho, D; Choueiri, TK; Coates, A; Ernstoff, MS; Gupta, N; Kollmannsberger, CK; Michaelson, MD; Perry, DJ; Posadas, EM; Pradhan, R; Qian, J; Ricker, JL; Scappaticci, FA; Tannir, NM; Wong, YN	1
Koc, G; Luo, Y; Wang, X	1
Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S	1
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C	1
B Cohen, R; Olszanski, AJ; Patson, B	1
Bruyere, F; Carmier, D; Combe, P; D'Arcier, BF; Linassier, C; Narciso, B	1
Buonerba, C; De Placido, S; Di Lorenzo, G	1
Nystrom, KK; Pick, AM	1
Gupta, GN; Singer, EA; Srinivasan, R	1
Becze, E	1
Haddad, H; Rini, BI	1
Powles, T	1
Fujioka, T; Iwasaki, K; Obara, W	1
Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K	1
Carmichael, C; Josephson, DY; Lau, C; Pal, SK	1
Beijnen, JH; Schellens, JH; van Geel, RM	1
Shariat, SF; Xylinas, E	1
Amado, RG; Baker-Neblett, KL; Figlin, RA; Heymach, JV; Hutson, TE; Lin, Y; Liu, Y; Martin, AM; Pandite, LN; Sternberg, CN; Tran, HT; Zurita, AJ	1
Boleti, E; Chowdury, S; Crabb, SJ; Jones, R; Nathan, P; Powles, T; Protheroe, A; Rashid, S; Sarwar, N; Shamash, J; Stockdale, A; Wilson, P	1
Atkins, MB; Choueiri, TK; Doyle, LA; Klempner, SJ; Schuppan, D; Yee, E	1
Cerbone, L; Recine, F; Sternberg, CN; Zivi, A	1
Carmichael, C; Ferrell, B; Hsu, J; Lau, C; Liu, X; Pal, SK; Saikia, J; Sun, V; Wilson, T; Yuh, BE	1
Amarantidis, K; Chamalidou, E; Chelis, L; Christakidis, E; Dimopoulos, P; Kakolyris, S; Michailidis, P; Prassopoulos, P; Souftas, V; Xenidis, N	1
Bowles, DW; Flaig, TW; Jimeno, A; Kessler, ER; Lam, ET	1
Matsunaga, H; Matsushita, A; Nakamura, H; Ohba, K; Oki, Y; Ozono, S; Sasaki, S; Takayama, T	1
Lin, CC; Pu, YS; Wang, JY	1
McKeage, K; Yang, LP	1
Asaithambi, G; Hurliman, E; Khan, AS; Moran, BP; Peters, BR; Taylor, RA	1
Cappelleri, JC; Chen, C; Foley, G; Healey, PJ; Kroes, M; Larkin, J; Mitchell, S; Paine, A; Tumur, I	1
Borker, R; Fonseca, E; Hess, G	1
Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z	1
Mittal, K; Rini, B	1
Brugarolas, J; Jacobs, C; Kim, DW; Straka, C; Timmerman, RD	1
Barrios, CH; Chen, M; Davis, ID; Gladkov, OA; Hawkins, RE; Lee, E; Mardiak, J; McCann, L; Rubin, SD; Salman, P; Sternberg, CN; Szczylik, C; Wagstaff, J; Zarba, JJ	1
Bissett, D; Elders, A; Fraser, C; Hislop, J; Kilonzo, M; McClinton, S; Mowatt, G; Vale, L	1
Andrews, L; Fishman, M; Gorbunova, V; Jonasch, E; Larkin, J; Negrier, S; Olivier, K; Pyle, L; Staehler, M; Wood, L	1
Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P	1
Bloom, J; Bycott, P; de La Motte Rouge, T; Grünwald, V; Harzstark, AL; Ingrosso, A; Kim, S; Liu, G; Michaelson, MD; Motzer, RJ; Rini, BI; Tortorici, MA	1
Cho, YS; Chun, YS; Kim, J; Kim, MS; Lee, JC; Park, JW; Yeo, EJ	1
Kanetake, H; Koga, S	1
Chew, K; Fong, K; Jaeger, E; Rini, BI; Sein, N; Simko, J; Small, EJ; Waldman, FM; Weinberg, V	1
Eto, M; Naito, S	1
Mancuso, A; Sternberg, CN	1
George, DJ	1
Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L	1
Bolte, O; Bukowski, RM; Bycott, P; Freddo, J; Hudes, GR; Kim, S; Liau, KF; Michaelson, MD; Motzer, RJ; Rini, BI; Rixe, O; Trask, PC; Wilding, G	1
Linehan, WM	1
Hutson, TE; Rini, BI; Sonpavde, G	1
Becker, H; Hoffmann, L; Köllermann, M; Müller, W; Possinger, K; Schlichter, A; Schmoll, E; Stahl, M; Wagner, H; Weidenhammer, W	1
Band, PR; Besner, JG; Coppin, CM; Eisenhauer, EA; Stewart, D; Weinerman, BH	1

Reviews

107 review(s) available for indazoles and Kidney Neoplasms

Article	Year
Gastrointestinal: Diarrhea in a patient treated with pazopanib: A rare case of a common adverse effect. Journal of gastroenterology and hepatology, 2023, Volume: 38, Issue:8 Topics: Angiogenesis Inhibitors; Diarrhea; Gastrointestinal Tract; Humans; Indazoles; Kidney Neoplasms; Pyrimidines	2023
Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review. Clinical genitourinary cancer, 2019, Volume: 17, Issue:6 Topics: Aged; Antineoplastic Agents, Immunological; Axons; Carcinoma, Renal Cell; Drug Substitution; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Motor Neurons; Nivolumab; Paraparesis; Polyneuropathies; Pyrimidines; Skin Neoplasms; Sulfonamides	2019
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review. Clinical genitourinary cancer, 2019, Volume: 17, Issue:6 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Humans; Hypertension; Indazoles; Kidney Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2019
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer treatment reviews, 2020, Volume: 84 Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib	2020
Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure. Current opinion in supportive and palliative care, 2020, Volume: 14, Issue:3 Topics: Anilides; Axitinib; Carcinoma, Renal Cell; Drug Therapy, Combination; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases	2020
Targeted therapy for metastatic renal cell carcinoma. The Cochrane database of systematic reviews, 2020, 10-14, Volume: 10 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Axitinib; Bevacizumab; Bias; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2020
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting. Future oncology (London, England), 2017, Volume: 13, Issue:21 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Retreatment; Treatment Outcome	2017
Second-line systemic therapy in metastatic renal-cell carcinoma: A review. Urologic oncology, 2017, Volume: 35, Issue:11 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib	2017
Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug design, development and therapy, 2017, Volume: 11 Topics: Axitinib; Carcinoma, Renal Cell; Drug Discovery; Drug Interactions; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2017
Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma. Critical reviews in oncology/hematology, 2018, Volume: 121 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis	2018
Kidney cancer in 2017: Challenging and refining treatment paradigms. Nature reviews. Urology, 2018, Volume: 15, Issue:2 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents, Immunological; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; CTLA-4 Antigen; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Nephrectomy; Nivolumab; Programmed Cell Death 1 Receptor; Pyridines; Pyrimidines; Sulfonamides	2018
The Impact of Pazopanib on the Cardiovascular System. Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cardiovascular Diseases; Cardiovascular System; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Risk Assessment; Risk Factors; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome	2018
Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature. Clinical genitourinary cancer, 2018, Volume: 16, Issue:5 Topics: Anilides; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Middle Aged; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome	2018
Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review. PharmacoEconomics, 2019, Volume: 37, Issue:3 Topics: Carcinoma, Renal Cell; Cost of Illness; Cost-Benefit Analysis; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Time Factors	2019
Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC pharmacology & toxicology, 2018, Nov-26, Volume: 19, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Quality of Life; Sulfonamides; Treatment Outcome	2018
Adjuvant therapy after nephrectomy for renal cell carcinoma. Asia-Pacific journal of clinical oncology, 2018, Volume: 14 Suppl 5 Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Progression-Free Survival; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib	2018
Bulletin du cancer, 2018, Volume: 105 Suppl 3 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Nivolumab; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib	2018
Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:1 Topics: Adult; Aged; Carcinoma, Renal Cell; Chordoma; Female; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Skull Base Neoplasms; Sulfonamides	2020
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis. BMC cancer, 2019, May-23, Volume: 19, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Health Care Costs; Humans; Indazoles; Kidney Neoplasms; Liver; Middle Aged; Neutropenia; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome	2019
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. Future oncology (London, England), 2019, Volume: 15, Issue:22 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma. Clinical pharmacology and therapeutics, 2020, Volume: 107, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Decision Making; Drug Approval; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Risk Assessment; Sulfonamides; United States; United States Food and Drug Administration	2020
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anti-cancer drugs, 2013, Volume: 24, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid	2013
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert review of anticancer therapy, 2013, Volume: 13, Issue:6 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Palliative Care; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases	2013
Side-effects associated with targeted therapies in renal cell carcinoma. Current opinion in supportive and palliative care, 2013, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib	2013
Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Seminars in oncology, 2013, Volume: 40, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib	2013
Molecular markers to predict response to therapy. Seminars in oncology, 2013, Volume: 40, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein	2013
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:11 Topics: Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides	2013
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer treatment reviews, 2014, Volume: 40, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Induction Chemotherapy; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2014
Axitinib for the treatment of advanced renal cell carcinoma. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:2 Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Rate	2014
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. International journal of cancer, 2015, Jan-01, Volume: 136, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib	2015
Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:7 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quality of Life; Sirolimus; Vascular Endothelial Growth Factor A	2014
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert opinion on drug safety, 2014, Volume: 13, Issue:4 Topics: Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2014
Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2014 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Patient Selection; Sirolimus; Treatment Outcome	2014
Pazopanib: a review of its use in the management of advanced renal cell carcinoma. Drugs, 2014, Volume: 74, Issue:10 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Sulfonamides	2014
Common questions regarding clinical use of axitinib in advanced renal cell carcinoma. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Jul-01, Volume: 71, Issue:13 Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Pharmaceutical Solutions; Protein Kinase Inhibitors	2014
[Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas]. Bulletin du cancer, 2014, Volume: 101, Issue:6 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sarcoma; Sulfonamides	2014
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. BMC cancer, 2014, Aug-15, Volume: 14 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis	2014
[Axitinib in metastatic renal carcinomas: update of knowledge about side effects]. Bulletin du cancer, 2014, Volume: 101, Issue:10 Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2014
Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews. Urology, 2015, Volume: 12, Issue:2 Topics: Angiogenesis Inhibitors; Carcinogenesis; Carcinoma, Renal Cell; Disease Progression; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Nephrons; Organ Sparing Treatments; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2015
Pazopanib for the treatment of renal cell carcinoma. Future oncology (London, England), 2015, Volume: 11, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2015
Axitinib in metastatic renal cell carcinoma. Expert review of anticancer therapy, 2015, Volume: 15, Issue:5 Topics: Algorithms; Axitinib; Carcinoma, Renal Cell; Disease Progression; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor	2015
Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma. Expert opinion on drug discovery, 2015, Volume: 10, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor	2015
First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES. Current opinion in urology, 2015, Volume: 25, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Signal Transduction; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome	2015
Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment. International journal of urology : official journal of the Japanese Urological Association, 2016, Volume: 23, Issue:1 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Metastasectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Pyrroles; Sunitinib	2016
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?]. Aktuelle Urologie, 2015, Volume: 46, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2015
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews. Clinical genitourinary cancer, 2016, Volume: 14, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2016
Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials. Clinical oncology (Royal College of Radiologists (Great Britain)), 2016, Volume: 28, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Quinolines; Quinolones; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A	2016
Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report. Current drug targets, 2016, Volume: 17, Issue:15 Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Half-Life; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Pyrimidines; Renal Dialysis; Sulfonamides; Treatment Outcome	2016
Axitinib for the treatment of metastatic renal cell carcinoma. Future oncology (London, England), 2016, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy	2016
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anti-cancer drugs, 2016, Volume: 27, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2016
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism]. Der Urologe. Ausg. A, 2016, Volume: 55, Issue:5 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib	2016
Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib	2016
Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment. BMC urology, 2016, Jul-04, Volume: 16, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome	2016
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:12 Topics: Aged; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Interactions; Drug Monitoring; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Sarcoma; Sulfonamides	2016
Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Axitinib; Carcinoma, Renal Cell; Everolimus; Fatal Outcome; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Middle Aged; Nephrotic Syndrome; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides	2017
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer treatment reviews, 2016, Volume: 50 Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2016
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. European urology, 2017, Volume: 71, Issue:3 Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2017
Targeted Therapy for Metastatic Renal Cell Carcinoma. Acta medica Indonesiana, 2016, Volume: 48, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2016
Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Alopecia; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Hair Color; Humans; Indazoles; Kidney Neoplasms; Male; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides	2017
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult	2017
Novel drugs for renal cell carcinoma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2008
Targeted therapies in metastatic renal cancer in 2009. BJU international, 2009, Volume: 103, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors	2009
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer, 2009, May-15, Volume: 115, Issue:10 Suppl Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2009
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome	2009
Pazopanib: therapeutic developments. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:18 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indazoles; Kidney Neoplasms; Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vascular Endothelial Growth Factors	2009
Pazopanib for the treatment of renal cell carcinoma and other malignancies. Drugs of today (Barcelona, Spain : 1998), 2009, Volume: 45, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Indazoles; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides	2009
Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:6 Topics: Administration, Oral; Animals; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides	2010
Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert review of anticancer therapy, 2010, Volume: 10, Issue:5 Topics: Animals; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sulfonamides	2010
Pazopanib: in advanced renal cell carcinoma. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2010, Oct-01, Volume: 24, Issue:5 Topics: Anticarcinogenic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides	2010
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? Expert review of anticancer therapy, 2010, Volume: 10, Issue:10 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors	2010
Pazopanib in renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Dec-15, Volume: 16, Issue:24 Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2010
The therapy of kidney cancer with biomolecular drugs. Cancer treatment reviews, 2010, Volume: 36 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indazoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases	2010
[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines]. Magyar onkologia, 2010, Volume: 54, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Europe; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2010
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs, 2011, Mar-05, Volume: 71, Issue:4 Topics: Animals; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Treatment Outcome	2011
[Novelties in the treatment for advanced renal-cell cancer]. Orvosi hetilap, 2011, Apr-24, Volume: 152, Issue:17 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
Pazopanib for the treatment of renal cancer. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:7 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sulfonamides	2011
[Treatment of metastatic renal cell carcinoma]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2011, Volume: 21, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2011
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. Clinical therapeutics, 2011, Volume: 33, Issue:6 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib	2011
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematology/oncology clinics of North America, 2011, Volume: 25, Issue:4 Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2011
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?]. Bulletin du cancer, 2011, Volume: 98, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib	2011
[Systemic treatment of renal cell carcinoma - recent update]. Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:15-16 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Evidence-Based Medicine; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Palliative Care; Phenylurea Compounds; Practice Guidelines as Topic; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib	2011
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-01, Volume: 17, Issue:21 Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2011
Axitinib in the treatment of metastatic renal cell carcinoma. Future oncology (London, England), 2011, Volume: 7, Issue:11 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Receptors, Vascular Endothelial Growth Factor	2011
Tyrosine kinase inhibitors for metastatic renal cell carcinoma. Drug and therapeutics bulletin, 2011, Volume: 49, Issue:11 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2011
Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma. The Canadian journal of urology, 2011, Volume: 18, Issue:6 Topics: Administration, Oral; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indazoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides; Treatment Outcome	2011
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing	2012
Pharmacokinetic evaluation of axitinib. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:2 Topics: Animals; Axitinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Pancreatic Neoplasms; Protein Kinase Inhibitors; Thyroid Neoplasms	2012
Pazopanib for the treatment of metastatic renal cell carcinoma. Clinical therapeutics, 2012, Volume: 34, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides; Treatment Outcome	2012
Targeted therapeutic strategies for the management of renal cell carcinoma. Current opinion in oncology, 2012, Volume: 24, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Tuberous Sclerosis; United States	2012
Current treatment considerations in metastatic renal cell carcinoma. Current treatment options in oncology, 2012, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of Der Urologe. Ausg. A, 2012, Volume: 51, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides	2012
Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma. Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:5 Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasms; Protein Kinase Inhibitors	2012
Concise drug review: pazopanib and axitinib. The oncologist, 2012, Volume: 17, Issue:8 Topics: Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Meta-Analysis as Topic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; United States; United States Food and Drug Administration	2012
Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Expert opinion on drug safety, 2012, Volume: 11, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Evaluation; Drug Monitoring; Humans; Indazoles; Kidney Neoplasms; Neoplasm Proteins; Pharmacovigilance; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Sulfonamides; Up-Regulation; Vascular Endothelial Growth Factor A	2012
Axitinib, a new therapeutic option in renal cell carcinoma. Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48, Issue:10 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas	2012
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Treatment Outcome; Young Adult	2013
Kidney cancer in 2012: new frontiers in kidney cancer research. Nature reviews. Urology, 2013, Volume: 10, Issue:2 Topics: Animals; Axitinib; Biomedical Research; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Imidazoles; Immunotherapy; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2013
Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal. PharmacoEconomics, 2013, Volume: 31, Issue:1 Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Decision Making; Drug Approval; Drug Costs; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Technology Assessment, Biomedical; United Kingdom	2013
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. American journal of clinical oncology, 2014, Volume: 37, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2	2014
SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clinical genitourinary cancer, 2005, Volume: 4, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib	2005
[Progress in therapeutic strategy for renal cell carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib	2006
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Current oncology reports, 2006, Volume: 8, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2006
Molecular targeting therapy for renal cell carcinoma. International journal of clinical oncology, 2006, Volume: 11, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib	2006
New treatment approaches in metastatic renal cell carcinoma. Current opinion in urology, 2006, Volume: 16, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2006
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jan-15, Volume: 13, Issue:2 Pt 2 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cytokines; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Phenotype; Platelet-Derived Growth Factor; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2007
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:2 Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides	2008
Axitinib for renal cell carcinoma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Evaluation; Humans; Imidazoles; Indazoles; Kidney Neoplasms	2008

Trials

99 trial(s) available for indazoles and Kidney Neoplasms

Article	Year
Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. BMC cancer, 2021, Sep-14, Volume: 21, Issue:1 Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Asia; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Middle East; Progression-Free Survival; Prospective Studies; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Young Adult	2021
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group. Clinical genitourinary cancer, 2022, Volume: 20, Issue:4 Topics: B7-H1 Antigen; Biomarkers; Carcinoma, Renal Cell; Humans; Indazoles; Interferon-alpha; Kidney Neoplasms; Prognosis; Pyrimidines; Sulfonamides; Treatment Outcome; Tumor Necrosis Factor-alpha	2022
A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial. Clinical genitourinary cancer, 2022, Volume: 20, Issue:5 Topics: Adolescent; Adult; Aged; Carcinoma, Renal Cell; Humans; Immune Checkpoint Inhibitors; Indazoles; Kidney Neoplasms; Prospective Studies; Pyrimidines; Sulfonamides	2022
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. European urology oncology, 2021, Volume: 4, Issue:3 Topics: Biomarkers; Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2021
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clinical genitourinary cancer, 2019, Volume: 17, Issue:6 Topics: Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Kidney Neoplasms; Logistic Models; Male; Pyrimidines; Random Allocation; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2019
A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ). Urologia internationalis, 2020, Volume: 104, Issue:3-4 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrimidines; Sulfonamides; Sunitinib; Treatment Failure; Treatment Outcome	2020
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. Clinical pharmacokinetics, 2020, Volume: 59, Issue:7 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Prospective Studies; Pyrimidines; Sulfonamides	2020
Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response. Clinical and experimental medicine, 2020, Volume: 20, Issue:2 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diffusion Magnetic Resonance Imaging; Female; Healthy Volunteers; Humans; Indazoles; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Retrospective Studies; ROC Curve; Sulfonamides; Treatment Outcome	2020
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. BMC cancer, 2020, Mar-14, Volume: 20, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; China; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Sulfonamides; Sunitinib; Young Adult	2020
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bulletin du cancer, 2020, Volume: 107, Issue:5S Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Neoplasm Metastasis; Nivolumab; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib	2020
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. International journal of cancer, 2021, 02-15, Volume: 148, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Hypothyroidism; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome	2021
Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI insight, 2020, 11-19, Volume: 5, Issue:22 Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Case-Control Studies; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate; Transcriptome	2020
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European urology, 2021, Volume: 79, Issue:3 Topics: Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Neoplasm Recurrence, Local; Nephrectomy; Pyrimidines; Sulfonamides	2021
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES. American journal of clinical oncology, 2021, 04-01, Volume: 44, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Follow-Up Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Quality of Life; Sulfonamides; Sunitinib; Testosterone	2021
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. International journal of cancer, 2021, 07-15, Volume: 149, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Interleukin-10; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Polyethylene Glycols; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult	2021
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical genitourinary cancer, 2021, Volume: 19, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome	2021
A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients. CPT: pharmacometrics & systems pharmacology, 2017, Volume: 6, Issue:6 Topics: Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Models, Biological; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2017
Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava. International journal of clinical oncology, 2018, Volume: 23, Issue:1 Topics: Aged; Axitinib; Blood Loss, Surgical; Carcinoma, Renal Cell; Female; Fibrosis; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Postoperative Complications; Preoperative Care; Retrospective Studies; Thrombosis; Vena Cava, Inferior; Venous Thrombosis	2018
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. BMC cancer, 2017, Aug-15, Volume: 17, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Monitoring; Female; Humans; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Sulfonamides; Treatment Outcome	2017
Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. European journal of cancer (Oxford, England : 1990), 2017, Volume: 85 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Diffusion Magnetic Resonance Imaging; Drug Dosage Calculations; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Time Factors; Treatment Outcome	2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Dec-10, Volume: 35, Issue:35 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Nephrectomy; Placebos; Pyrimidines; Sulfonamides; Young Adult	2017
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiation oncology (London, England), 2017, Sep-22, Volume: 12, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrimidines; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Sulfonamides	2017
Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort. World journal of urology, 2018, Volume: 36, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Regression Analysis; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib; Treatment Outcome; Tumor Burden	2018
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. Journal of hematology & oncology, 2018, 05-22, Volume: 11, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Sunitinib; White People; Young Adult	2018
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British journal of cancer, 2018, Volume: 119, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyridines; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome	2018
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British journal of cancer, 2018, Volume: 119, Issue:6 Topics: Carcinoma, Transitional Cell; DNA Copy Number Variations; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Kidney Neoplasms; Male; Microtubule-Associated Proteins; Mutation; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Sequence Analysis, DNA; Sulfonamides; Survival Analysis; Treatment Outcome; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein	2018
Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. Clinical drug investigation, 2018, Volume: 38, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Canada; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Pyrimidines; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Treatment Outcome	2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer, 2018, 10-22, Volume: 6, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyrimidines; Sulfonamides; Sunitinib	2018
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. International journal of clinical oncology, 2019, Volume: 24, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2019
Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma. Investigational new drugs, 2019, Volume: 37, Issue:2 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Combined Modality Therapy; Diet, Fat-Restricted; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Sulfonamides	2019
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European journal of cancer (Oxford, England : 1990), 2019, Volume: 107 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Patient Safety; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Survival Rate; Young Adult	2019
Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib. Anticancer research, 2019, Volume: 39, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Incidence; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Outpatients; Patient Compliance; Pyrimidines; Self Report; Sulfonamides; Treatment Outcome	2019
Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol. Health and quality of life outcomes, 2019, Feb-04, Volume: 17, Issue:1 Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult	2019
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. European urology oncology, 2020, Volume: 3, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Risk Assessment; Single-Blind Method; Sirolimus; Sulfonamides	2020
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Self Report; Sorafenib; Treatment Outcome; Young Adult	2013
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Withholding Treatment	2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:6 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Quality of Life; Sorafenib; Surveys and Questionnaires; Time Factors; Treatment Outcome	2013
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult	2013
Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clinical genitourinary cancer, 2013, Volume: 11, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome	2013
Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Combined Modality Therapy; Double-Blind Method; Female; Humans; Indazoles; Kidney; Kidney Neoplasms; Kinetics; Logistic Models; Male; Middle Aged; Models, Biological; Pharmacogenetics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tumor Burden	2013
Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma. Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sulfonamides; Sunitinib; Survival Rate; Treatment Failure	2014
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-15, Volume: 19, Issue:18 Topics: Angiogenesis Inhibitors; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA, Neoplasm; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Indazoles; Kidney Neoplasms; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Pyrimidines; Signal Transduction; Sulfonamides; Survival Rate; Von Hippel-Lindau Tumor Suppressor Protein	2013
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. The New England journal of medicine, 2013, Aug-22, Volume: 369, Issue:8 Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib	2013
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Imidazoles; Indazoles; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; United States	2013
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Confounding Factors, Epidemiologic; Disease-Free Survival; Europe; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; North America; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Research Design; Severity of Illness Index; Sorafenib; Treatment Outcome	2013
Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. European urology, 2014, Volume: 66, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Biopsy; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Texas; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Targeted oncology, 2015, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib	2015
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, May-10, Volume: 32, Issue:14 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Over Studies; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Patient Preference; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Surveys and Questionnaires	2014
Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug Interactions; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2014
[First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of pat Der Urologe. Ausg. A, 2014, Volume: 53, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Rate; Young Adult	2014
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. The New England journal of medicine, 2014, May-01, Volume: 370, Issue:18 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. British journal of cancer, 2014, Jun-10, Volume: 110, Issue:12 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden	2014
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. Oncology, 2014, Volume: 87, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anorexia; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hair Color; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Pyrimidines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides; Treatment Outcome	2014
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Cancer science, 2014, Volume: 105, Issue:12 Topics: Adult; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Vascular Endothelial Growth Factor Receptor-2	2014
Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma. Clinical pharmacokinetics, 2015, Volume: 54, Issue:4 Topics: Aged; Algorithms; Axitinib; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Linear Models; Male; Middle Aged; Protein Kinase Inhibitors	2015
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib]. Der Urologe. Ausg. A, 2015, Volume: 54, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib	2015
Proteinuria with first-line therapy of metastatic renal cell cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrimidines; Retrospective Studies; Sulfonamides	2016
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-01, Volume: 21, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Female; Gene Expression; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Lymphocyte Count; Macrophages; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2015
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Calcium-Binding Proteins; Carcinoma, Renal Cell; China; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A	2015
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7 Topics: Axitinib; Blood Pressure; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Survival Rate; Tissue Distribution	2015
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. The Journal of urology, 2015, Volume: 194, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Indazoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Organ Size; Prospective Studies; Pyrimidines; Retrospective Studies; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2015
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2015, Volume: 13, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Axitinib; Blood Pressure; Carcinoma, Renal Cell; Disease-Free Survival; Female; Genetic Association Studies; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Linkage Disequilibrium; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2015
Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial. BJU international, 2016, Volume: 117, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Observer Variation	2016
Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib. Oncology, 2015, Volume: 89, Issue:4 Topics: Adolescent; Albumins; Alkaline Phosphatase; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Humans; Indazoles; Kidney Neoplasms; Nomograms; Prognosis; Pyrimidines; Sulfonamides	2015
Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2015, Volume: 13, Issue:6 Topics: Axitinib; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective Studies	2015
Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer, 2016, Jan-15, Volume: 122, Issue:2 Topics: Adult; Aged; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indazoles; Indoles; Kidney Neoplasms; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Risk Assessment; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome	2016
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. International journal of cancer, 2016, May-01, Volume: 138, Issue:9 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? European journal of cancer (Oxford, England : 1990), 2016, Volume: 53 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2016
Benefits of pazopanib over sunitinib for renal cell carcinoma. The Lancet. Oncology, 2016, Volume: 17, Issue:3 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Patient Safety; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Sensitivity and Specificity; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2016
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer, 2016, Apr-01, Volume: 122, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Young Adult	2016
Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. Bulletin of experimental biology and medicine, 2016, Volume: 160, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Calpain; Carcinoma, Renal Cell; Everolimus; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Nephrectomy; NF-kappa B; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2016
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. British journal of cancer, 2016, 06-14, Volume: 114, Issue:12 Topics: Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proteinuria; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A	2016
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Double Bind Interaction; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome	2016
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. JAMA oncology, 2016, Oct-01, Volume: 2, Issue:10 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Proportional Hazards Models; Pyrimidines; Sulfonamides; Treatment Outcome	2016
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome	2017
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Contrast Media; Disease Progression; Female; Humans; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome	2017
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial. JAMA oncology, 2017, Apr-01, Volume: 3, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Quality of Life; Sulfonamides	2017
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult	2017
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Acetylation; Adult; Aged; Alanine Transaminase; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Benzofurans; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Drug Resistance; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fatigue; Female; Gene Expression; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pyrimidines; Sulfonamides; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult	2017
Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. Cancer science, 2017, Volume: 108, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Outcome	2017
Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Quality of Life; Surveys and Questionnaires	2008
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2009
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-20, Volume: 28, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sulfonamides; Treatment Outcome	2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Renal Cell; Double-Blind Method; Female; Humans; Indazoles; International Agencies; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome; Young Adult	2010
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. Journal of hepatology, 2011, Volume: 54, Issue:6 Topics: Aged; Alanine Transaminase; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Genes, MHC Class I; Genes, MHC Class II; Genetic Markers; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Indazoles; Kidney Neoplasms; Male; Membrane Proteins; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrimidines; Sulfonamides	2011
[Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or loc Der Urologe. Ausg. A, 2011, Volume: 50, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Double-Blind Method; Germany; Humans; Indazoles; Kidney Neoplasms; Nephrectomy; Placebo Effect; Prevalence; Pyrimidines; Risk Assessment; Risk Factors; Sulfonamides; Survival Analysis; Survival Rate	2011
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Health Status; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Quality of Life; Sulfonamides	2012
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. Clinical therapeutics, 2011, Volume: 33, Issue:6 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib	2011
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proteinuria; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-2	2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (London, England), 2011, Dec-03, Volume: 378, Issue:9807 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Young Adult	2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyrroles; Sunitinib; Treatment Failure	2011
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of Der Urologe. Ausg. A, 2012, Volume: 51, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides	2012
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2012
Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors. Clinical genitourinary cancer, 2013, Volume: 11, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Everolimus; Female; Humans; Immunosuppressive Agents; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrimidines; Quality of Life; Sirolimus; Sulfonamides; Surveys and Questionnaires; Survivors; Treatment Outcome	2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome	2013
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clinical genitourinary cancer, 2013, Volume: 11, Issue:2 Topics: Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Survival Rate; Treatment Outcome	2013
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet. Oncology, 2007, Volume: 8, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Imidazoles; Indazoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment Outcome	2007
Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study. Seminars in oncology, 1991, Volume: 18, Issue:2 Suppl 4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Evaluation; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Tamoxifen; Time Factors	1991
Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer treatment reports, 1986, Volume: 70, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nausea; Pain; Pyrazoles; Testis; Testosterone	1986

Other Studies

347 other study(ies) available for indazoles and Kidney Neoplasms

Article	Year
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma. Anti-cancer drugs, 2022, 01-01, Volume: 33, Issue:1 Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disseminated Intravascular Coagulation; Humans; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nivolumab; Pyrimidines; Sulfonamides	2022
Pazopanib-induced severe acute liver injury: A case report. Medicine, 2021, Nov-19, Volume: 100, Issue:46 Topics: Bilirubin; Biopsy; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Female; Hepatitis B; Humans; Indazoles; Jaundice; Kidney Neoplasms; Middle Aged; Nausea; Pyrimidines; Steroids; Sulfonamides; Tomography, X-Ray Computed; Ultrasonography; United States; Vomiting	2021
Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:2 Topics: Aged; Ascites; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome	2022
Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety. International journal of molecular sciences, 2022, Aug-31, Volume: 23, Issue:17 Topics: Amino Acids; Antineoplastic Agents; Carcinoma, Renal Cell; Glycerophospholipids; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2022
Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors. Oncotarget, 2022, Volume: 13 Topics: Anilides; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Nerve Growth Factors; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinolines; src-Family Kinases; Sulfonamides; Sunitinib	2022
Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy. Cancer research and treatment, 2023, Volume: 55, Issue:2 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Republic of Korea; Treatment Outcome	2023
Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib. Anticancer research, 2023, Volume: 43, Issue:2 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Lipomatosis; Protein Kinase Inhibitors; Sunitinib	2023
Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma. Scientific reports, 2023, 02-06, Volume: 13, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; East Asian People; Humans; Indazoles; Kidney Neoplasms; Sarcoma; Soft Tissue Neoplasms	2023
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? Expert review of anticancer therapy, 2023, Volume: 23, Issue:5 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Retrospective Studies; Treatment Outcome	2023
Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 04-10, Volume: 41, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib	2023
Pharmacist-Urologist Collaborative Management for Patients with Renal Cell Carcinoma Receiving Pazopanib Monotherapy. Biological & pharmaceutical bulletin, 2023, Volume: 46, Issue:8 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pharmacists; Retrospective Studies; Treatment Outcome; Urologists	2023
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment. Urologic oncology, 2023, Volume: 41, Issue:11 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Treatment Outcome	2023
Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer. Frontiers in immunology, 2023, Volume: 14 Topics: Carcinoma, Renal Cell; Humans; Immune Checkpoint Inhibitors; Indazoles; Kidney Neoplasms	2023
[Cost-effectiveness between pazopanib and sunitinib for metastatic renal cancer from the perspective of the Brazilian Unified National Health System]. Cadernos de saude publica, 2019, Aug-22, Volume: 35, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; National Health Programs; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome	2019
Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration. Cancer medicine, 2019, Volume: 8, Issue:15 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States; United States Department of Veterans Affairs	2019
Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma. BMC cancer, 2019, Oct-17, Volume: 19, Issue:1 Topics: Acetates; Aged, 80 and over; Calcium Compounds; Carcinoma, Renal Cell; Exocrine Pancreatic Insufficiency; Gastrointestinal Agents; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Oxalates; Pancreatic Neoplasms; Pancrelipase; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Sulfonamides; Treatment Outcome	2019
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America. Advances in therapy, 2019, Volume: 36, Issue:12 Topics: Aged; Carcinoma, Renal Cell; Disease Progression; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Latin America; Male; Middle Aged; Neoplasm Metastasis; Practice Patterns, Physicians'; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Time-to-Treatment	2019
Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. Clinical genitourinary cancer, 2020, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Function Tests; Longitudinal Studies; Male; Middle Aged; Polymorphism, Genetic; Progression-Free Survival; Prospective Studies; Pyrimidines; Retrospective Studies; Sulfonamides	2020
Eyelashes depigmentation following treatment with pazopanib for metastatic renal cell carcinoma. Dermatologic therapy, 2019, Volume: 32, Issue:6 Topics: Carcinoma, Renal Cell; Eyelashes; Female; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Pigmentation Disorders; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2019
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma. Clinical genitourinary cancer, 2020, Volume: 18, Issue:1 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Time Factors	2020
Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Renal Cell; Drug Therapy, Combination; Edema; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sulfonamides; Synovitis	2020
Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:5 Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib	2020
Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Abdominal radiology (New York), 2020, Volume: 45, Issue:6 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome	2020
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report. Journal of medical case reports, 2020, Jan-11, Volume: 14, Issue:1 Topics: Humans; Indazoles; Kidney Neoplasms; Lung Abscess; Lung Neoplasms; Male; Middle Aged; Pyrimidines; Sulfonamides	2020
Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era. Clinical genitourinary cancer, 2020, Volume: 18, Issue:2 Topics: Adolescent; Adult; Age Factors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Young Adult	2020
Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma. Cell death & disease, 2020, 02-12, Volume: 11, Issue:2 Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Renal Cell; Cell Line, Tumor; Chemokine CCL24; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Kidney Neoplasms; Male; Mice, Inbred NOD; Mice, SCID; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Pyrimidines; Receptors, CCR3; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays	2020
Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer. Biological & pharmaceutical bulletin, 2020, May-01, Volume: 43, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Asian People; Carcinoma, Renal Cell; Drug Monitoring; Female; Humans; Indazoles; Japan; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult	2020
Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report. Anticancer research, 2020, Volume: 40, Issue:3 Topics: Aged; Anilides; Carcinoma, Renal Cell; Cysts; Humans; Indazoles; Kidney Neoplasms; Liver Diseases; Male; Neoplasm Metastasis; Pyridines; Pyrimidines; Sulfonamides	2020
Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:4 Topics: Aged; Carcinoma, Renal Cell; Drug Interactions; Humans; Hyperglycemia; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2020
Importance of Therapeutic Drug Monitoring to Detect Drug Interaction between Pazopanib and Warfarin: A Case Report. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2020, Volume: 23 Topics: Administration, Oral; Aged; Carcinoma, Renal Cell; Drug Interactions; Drug Monitoring; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Warfarin	2020
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. Urologic oncology, 2020, Volume: 38, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome	2020
Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma. British journal of cancer, 2020, Volume: 123, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; Indazoles; Kidney Neoplasms; Models, Theoretical; Piperazines; Pyrazoles; Signal Transduction; Small Molecule Libraries; Sulfonamides; Sunitinib	2020
Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. European journal of clinical pharmacology, 2020, Volume: 76, Issue:9 Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Histamine H2 Antagonists; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate; Time Factors; Treatment Outcome	2020
Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer. Pathology oncology research : POR, 2020, Volume: 26, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome	2020
Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma. Pathology oncology research : POR, 2020, Volume: 26, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Child; Female; Humans; Indazoles; Inflammation; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Platelet Count; Prognosis; Pyrimidines; Sulfonamides; Sunitinib; Young Adult	2020
Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation. Cancer medicine, 2020, Volume: 9, Issue:16 Topics: Anilides; Antineoplastic Agents; Arylsulfotransferase; Axitinib; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Chromogranins; Computer Simulation; Cyclin E; DNA Copy Number Variations; Drug Resistance, Neoplasm; GTP-Binding Protein alpha Subunits, Gs; Humans; Indazoles; Kidney Neoplasms; Oncogene Proteins; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib	2020
Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma. BMJ case reports, 2020, Jul-08, Volume: 13, Issue:7 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Pyrimidines; Sulfonamides	2020
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC cancer, 2020, Jul-17, Volume: 20, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom; Young Adult	2020
Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. Medical oncology (Northwood, London, England), 2020, Aug-07, Volume: 37, Issue:9 Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Nivolumab; Patient Selection; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib	2020
Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab. The Canadian journal of urology, 2020, Volume: 27, Issue:4 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bile Duct Diseases; Bile Ducts, Intrahepatic; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Syndrome	2020
Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study). American journal of clinical oncology, 2020, Volume: 43, Issue:9 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemokine CXCL12; Disease Progression; Drug Resistance, Neoplasm; E-Selectin; Female; Hepatocyte Growth Factor; Humans; Indazoles; Interleukin-6; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Osteopontin; Progression-Free Survival; Prospective Studies; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Survival Rate; Translational Research, Biomedical; Vascular Endothelial Growth Factor A	2020
MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PloS one, 2020, Volume: 15, Issue:9 Topics: Carcinoma, Renal Cell; Female; Gene Expression Profiling; Humans; Indazoles; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Pyrimidines; RNA, Messenger; Sulfonamides; Sunitinib; Survival Analysis	2020
Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. Journal of geriatric oncology, 2021, Volume: 12, Issue:2 Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Geriatric Assessment; Humans; Indazoles; Kidney Neoplasms; Male; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2021
An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. Journal of medical economics, 2020, Volume: 23, Issue:12 Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indazoles; Italy; Kidney Neoplasms; Pyrimidines; Quality-Adjusted Life Years; State Medicine; Sulfonamides; Sunitinib	2020
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study. Japanese journal of clinical oncology, 2021, Mar-03, Volume: 51, Issue:3 Topics: Adult; Aged; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indazoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome	2021
Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor. Anti-cancer drugs, 2021, 04-01, Volume: 32, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Panniculitis; Pyrimidines; Sulfonamides	2021
Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. Journal of geriatric oncology, 2021, Volume: 12, Issue:5 Topics: Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Treatment Outcome	2021
Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. World journal of urology, 2021, Volume: 39, Issue:8 Topics: Alanine Transaminase; Aspartate Aminotransferases; Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Karnofsky Performance Status; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nephrectomy; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer medicine, 2021, Volume: 10, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Female; Humans; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinolines; Retrospective Studies; Sulfonamides; Survival Rate; Treatment Outcome	2021
Photothermal therapy enhance the anti-mitochondrial metabolism effect of lonidamine to renal cell carcinoma in homologous-targeted nanosystem. Nanomedicine : nanotechnology, biology, and medicine, 2021, Volume: 34 Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indazoles; Indoles; Kidney Neoplasms; Mice; Mitochondria; Nanoparticles; Photothermal Therapy; Polymers; Silicon Dioxide; Xenograft Model Antitumor Assays	2021
Efficacy of axitinib rechallenge in metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association, 2021, Volume: 28, Issue:6 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Treatment Outcome	2021
[RENAL CELL CARCINOMA METASTASIS TO BLADDER DURING MOLECULAR TARGETED THERAPY WITH PAZOPANIB: REPORT OF TWO CASES]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2020, Volume: 111, Issue:2 Topics: Aged; Carcinoma, Renal Cell; Combined Modality Therapy; Cystectomy; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Pyrimidines; Sulfonamides; Treatment Outcome; Urinary Bladder Neoplasms	2020
Targeted therapy in Xp11 translocation renal cell carcinoma. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2021,Spring, Volume: 34, Issue:2 Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Crizotinib; Disease Progression; Everolimus; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Nivolumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Tomography, X-Ray Computed	2021
Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:33 European urology, 2021, Volume: 80, Issue:1 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Nephrectomy; Pyrimidines; Sulfonamides; Survival Analysis	2021
Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib. BMJ case reports, 2021, Jun-25, Volume: 14, Issue:6 Topics: Adult; Carcinoma, Renal Cell; Chromosomes, Human, X; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Translocation, Genetic	2021
Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clinical and translational medicine, 2021, Volume: 11, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immunomodulation; Indazoles; Kidney Neoplasms; Male; Myeloid-Derived Suppressor Cells; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Transcriptome; Tumor Cells, Cultured; Tumor Microenvironment	2021
Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue. Experimental oncology, 2021, Volume: 43, Issue:2 Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2021
[Pneumothorax during Pazopanib Therapy in a Patient with Soft Tissue Sarcoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:7 Topics: Aged; Humans; Indazoles; Kidney Neoplasms; Male; Pneumothorax; Pyrimidines; Sarcoma; Sulfonamides	2021
Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line. Targeted oncology, 2021, Volume: 16, Issue:5 Topics: Aged; Carcinoma, Renal Cell; Cardiovascular Agents; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clinical genitourinary cancer, 2022, Volume: 20, Issue:1 Topics: Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Male; Prospective Studies; Quality of Life; Registries; Retrospective Studies; Sunitinib; Treatment Outcome	2022
Pazopanib-induced chylothorax in a patient with renal cell carcinoma. Anti-cancer drugs, 2022, 01-01, Volume: 33, Issue:1 Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Chylothorax; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides	2022
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. Targeted oncology, 2017, Volume: 12, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Analysis; Tumor Burden; Young Adult	2017
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity. Urologic oncology, 2017, Volume: 35, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Young Adult	2017
Heart Failure: A Paraneoplastic Manifestation of Renal Cell Carcinoma - Reversed With Pazopanib. Clinical genitourinary cancer, 2017, Volume: 15, Issue:5 Topics: Carcinoma, Renal Cell; Drug Administration Schedule; Heart Failure; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Pyrimidines; Stroke Volume; Sulfonamides; Treatment Outcome	2017
Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage. BMJ case reports, 2017, Apr-17, Volume: 2017 Topics: Aged; Carcinoma, Renal Cell; Cerebral Hemorrhage; Decompressive Craniectomy; Female; Humans; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides; Treatment Outcome	2017
Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma. Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:6 Topics: Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Membranes, Artificial; Middle Aged; Protein Kinase Inhibitors; Renal Dialysis; Treatment Outcome	2017
Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers. Future oncology (London, England), 2017, Volume: 13, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Community Health Centers; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; United States	2017
Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2017, Volume: 23, Issue:11 Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Electromyography; Guillain-Barre Syndrome; Humans; Immunoglobulins, Intravenous; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Pyrimidines; Serologic Tests; Sulfonamides	2017
Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. European journal of cancer (Oxford, England : 1990), 2017, Volume: 79 Topics: Age Factors; Age of Onset; Antineoplastic Agents; Axitinib; Cancer Care Facilities; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Protein Kinase Inhibitors; Treatment Outcome	2017
Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study. BMC cancer, 2017, 05-22, Volume: 17, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobins; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Polycythemia; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Young Adult	2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urologic oncology, 2017, Volume: 35, Issue:9 Topics: Aged; Antineoplastic Agents; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome	2017
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PloS one, 2017, Volume: 12, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Rate; United Kingdom	2017
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:6 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome	2017
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. British journal of cancer, 2017, Aug-08, Volume: 117, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cytokines; E-Selectin; Female; Hemoglobins; Hepatocyte Growth Factor; Humans; Indazoles; Interleukin-6; Interleukin-8; Kidney Neoplasms; L-Lactate Dehydrogenase; Leukocyte Count; Male; Middle Aged; Neutrophils; Osteopontin; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Time-to-Treatment; Tissue Inhibitor of Metalloproteinase-1; Tumor Burden; Vascular Endothelial Growth Factor A	2017
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. Clinical genitourinary cancer, 2017, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2017
Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region. Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:9 Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Rural Population; Sulfonamides; Sunitinib	2017
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. Current medical research and opinion, 2017, Volume: 33, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2017
[Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3]. Bulletin du cancer, 2017, Volume: 104, Issue:9 Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides	2017
Treatment of succinate dehydrogenase B-associated renal cancer. BMJ case reports, 2017, Aug-07, Volume: 2017 Topics: Adult; Antineoplastic Agents; Female; Germ-Line Mutation; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Succinate Dehydrogenase; Sulfonamides	2017
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? Drugs in R&D, 2017, Volume: 17, Issue:3 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome	2017
Renal cell carcinoma presenting as a cutaneous horn and nodules on the gingiva and scalp. BMJ case reports, 2017, Aug-18, Volume: 2017 Topics: Acute Kidney Injury; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diagnosis, Differential; Fatal Outcome; Gingiva; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Scalp; Skin Neoplasms; Sulfonamides	2017
Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. Clinical genitourinary cancer, 2017, Volume: 15, Issue:6 Topics: Adult; Aged; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome	2017
Axitinib-related osteonecrosis of the jaw. Oral surgery, oral medicine, oral pathology and oral radiology, 2017, Volume: 124, Issue:5 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Conservative Treatment; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Maxillary Diseases; Osteonecrosis; Protein Kinase Inhibitors; Radiography, Panoramic	2017
Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib. Japanese journal of clinical oncology, 2017, Dec-01, Volume: 47, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Risk Assessment; Treatment Outcome; Young Adult	2017
[Abnormal hair]. La Revue de medecine interne, 2019, Volume: 40, Issue:2 Topics: Carcinoma, Renal Cell; Female; Hair; Hair Color; Hair Diseases; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Pigmentation Disorders; Pyrimidines; Sulfonamides	2019
Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy. AJR. American journal of roentgenology, 2017, Volume: 209, Issue:6 Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Salvage Therapy; Sulfonamides; Tomography, X-Ray Computed	2017
Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma. Oncology research and treatment, 2017, Volume: 40, Issue:11 Topics: Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Cell-Free Nucleic Acids; Combined Modality Therapy; Disease-Free Survival; Everolimus; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Predictive Value of Tests; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2017
Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 12-10, Volume: 35, Issue:35 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Neoplasm Recurrence, Local; Nephrectomy; Pyrimidines; Sulfonamides	2017
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Advances in therapy, 2017, Volume: 34, Issue:11 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Health Expenditures; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States	2017
Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy. European journal of dermatology : EJD, 2017, 10-01, Volume: 27, Issue:5 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Leg Ulcer; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides	2017
Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model. Clinical and experimental hypertension (New York, N.Y. : 1993), 2018, Volume: 40, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Arterial Pressure; Body Weight; Carcinoma, Renal Cell; Cardiac Output; Disease Models, Animal; Echocardiography; Electrocardiography; Heart; Hypertension; Indazoles; Kidney; Kidney Neoplasms; Mice; Myocardium; Pyrimidines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sulfonamides; Vascular Endothelial Growth Factor A	2018
Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma. Cancer medicine, 2018, Volume: 7, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Decision-Making; Cost Sharing; Female; Health Expenditures; Health Services Accessibility; Humans; Indazoles; Kidney Neoplasms; Medicare Part D; Molecular Targeted Therapy; Patient Selection; Poverty; Pyrimidines; Retrospective Studies; Sulfonamides; Time Factors; United States	2018
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. Clinical genitourinary cancer, 2018, Volume: 16, Issue:3 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Prospective Studies; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome	2018
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. World journal of urology, 2018, Volume: 36, Issue:3 Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Nivolumab; Probability; Prognosis; Proportional Hazards Models; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sex Factors; Sulfonamides; Sunitinib; Survival Rate; Thrombocytosis	2018
Recurrent renal cell carcinoma presenting as a solitary left ventricular mass. The Canadian journal of urology, 2017, Volume: 24, Issue:6 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Heart Neoplasms; Heart Ventricles; Humans; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2017
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. Anticancer research, 2018, Volume: 38, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Czech Republic; Databases, Factual; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2018
[Atrial flutter probably related to pazopanib: A case report]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2018, 01-01, Volume: 42, Issue:1 Topics: Angiogenesis Inhibitors; Atrial Flutter; Carcinoma, Renal Cell; Electrocardiography; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Sarcoma; Sulfonamides	2018
Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites. Hypertension (Dallas, Tex. : 1979), 2018, Volume: 71, Issue:3 Topics: Administration, Oral; Aged; Carcinoma, Renal Cell; Cohort Studies; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glomerular Filtration Rate; Hospitals, University; Humans; Hypertension; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitric Oxide; Prospective Studies; Pyrimidines; Risk Assessment; Sulfonamides; Time Factors	2018
Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma. Clinical genitourinary cancer, 2018, Volume: 16, Issue:2 Topics: Aged; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Nivolumab; Pyrimidines; Sulfonamides; Treatment Outcome	2018
Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2018, Volume: 50 Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Hemangioblastoma; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; von Hippel-Lindau Disease	2018
Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report. Investigational new drugs, 2018, Volume: 36, Issue:3 Topics: Carcinoma, Renal Cell; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Patient Admission; Pyrimidines; Sulfonamides; Tumor Lysis Syndrome	2018
Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma. The oncologist, 2018, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Analysis	2018
Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 07-01, Volume: 24, Issue:13 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome	2018
Design, Synthesis, and Biological Evaluation of Axitinib Derivatives. Molecules (Basel, Switzerland), 2018, Mar-23, Volume: 23, Issue:4 Topics: Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor-2	2018
The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:4 Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Everolimus; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Nivolumab; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome	2018
Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus: a single-institution study. Anti-cancer drugs, 2018, Volume: 29, Issue:6 Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Retrospective Studies; Sulfonamides; Vena Cava, Inferior; Venous Thrombosis	2018
Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report. Clinical genitourinary cancer, 2018, Volume: 16, Issue:3 Topics: Adenoma, Oxyphilic; Administration, Oral; Combined Modality Therapy; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Treatment Outcome	2018
[Continuation of Axitinib for Advanced Renal Cell Carcinoma by The Application of Homecare Urology - A Case Report and Literature Review]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:4 Topics: Axitinib; Carcinoma, Renal Cell; Fatal Outcome; Home Care Services; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors	2018
Pazopanib-induced crystal deposition in intestinal mucosa in a patient with retroperitoneal liposarcoma. International journal of urology : official journal of the Japanese Urological Association, 2018, Volume: 25, Issue:6 Topics: Adult; Antineoplastic Agents; Edema; Endoscopy, Gastrointestinal; Humans; Indazoles; Intestinal Diseases; Intestinal Mucosa; Kidney Neoplasms; Liposarcoma; Male; Neoplasm Recurrence, Local; Pyrimidines; Retroperitoneal Neoplasms; Sulfonamides; Tomography, X-Ray Computed	2018
Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma. Clinical genitourinary cancer, 2018, Volume: 16, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult	2018
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway. Cancer immunology research, 2018, Volume: 6, Issue:6 Topics: B7-H1 Antigen; beta Catenin; Biomarkers; Carcinoma, Renal Cell; Cell Line, Tumor; Cytokines; Dendritic Cells; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Humans; Immunophenotyping; Indazoles; Kidney Neoplasms; Phagocytosis; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Sulfonamides; T-Lymphocytes	2018
Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. Medical oncology (Northwood, London, England), 2018, May-08, Volume: 35, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anilides; Axitinib; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyridines	2018
Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma. World journal of urology, 2018, Volume: 36, Issue:11 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Radiosurgery; Sulfonamides	2018
Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies. Acta clinica Belgica, 2019, Volume: 74, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Sectional Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Luteinizing Hormone; Male; Middle Aged; Molecular Targeted Therapy; Prevalence; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib; Testosterone; Vascular Endothelial Growth Factor A	2019
Re: Randomized Phase III Trial of Adjuvant Pazopanib versus Placebo after Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma. The Journal of urology, 2018, Volume: 199, Issue:6 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Nephrectomy; Pyrimidines; Sulfonamides	2018
Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models. Angiogenesis, 2018, Volume: 21, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kidney Neoplasms; Mice; Mice, SCID; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2018
Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Health Care Costs; Health Resources; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Patient Acceptance of Health Care; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome; United States	2018
A pneumoperitoneum due to intestinal cystic pneumatosis associated with a tyrosine kinase inhibitor. Revista espanola de enfermedades digestivas, 2018, Volume: 110, Issue:8 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Pneumoperitoneum; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed	2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU international, 2019, Volume: 123, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retreatment; Sulfonamides; Sunitinib; Survival Rate	2019
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. Anticancer research, 2018, Volume: 38, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Italy; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides	2018
Rapid and life-threatening heart failure induced by pazopanib. BMJ case reports, 2018, Aug-16, Volume: 2018 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Heart Failure; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides	2018
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma. International heart journal, 2018, Sep-26, Volume: 59, Issue:5 Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A	2018
Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma. Anticancer research, 2018, Volume: 38, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2018
Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population. Journal of global oncology, 2018, Volume: 4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brazil; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult	2018
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. Anticancer research, 2018, Volume: 38, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Autophagy; Autophagy-Related Proteins; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Liquid Biopsy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Polymorphism, Genetic; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate	2018
Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Clinical genitourinary cancer, 2019, Volume: 17, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Carcinoma, Renal Cell; Denosumab; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypocalcemia; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib	2019
Total necrosis after sequential treatment with pazopanib followed by nivolumab in a patient with renal cell carcinoma involving the inferior vena cava. International journal of urology : official journal of the Japanese Urological Association, 2019, Volume: 26, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Indazoles; Kidney; Kidney Neoplasms; Necrosis; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Nivolumab; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior	2019
Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib. Journal of Korean medical science, 2018, Dec-17, Volume: 33, Issue:51 Topics: Aged; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2018
Metastatic renal cell carcinoma presenting as a cardiac tumour. BMJ case reports, 2018, Dec-22, Volume: 11, Issue:1 Topics: Angiogenesis Inhibitors; Anticoagulants; Arrhythmias, Cardiac; Carcinoma, Renal Cell; Female; Heart Neoplasms; Heparin; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Palliative Care; Pyrimidines; Radiography, Thoracic; Sulfonamides; Tricuspid Valve Insufficiency; Tumor Burden	2018
Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma. Clinical genitourinary cancer, 2019, Volume: 17, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; ROC Curve; Sulfonamides; Survival Analysis; Treatment Outcome	2019
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European journal of cancer (Oxford, England : 1990), 2019, Volume: 108 Topics: Adult; Aged; Anilides; Antineoplastic Agents, Immunological; Axitinib; Carcinoma, Renal Cell; Female; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib; Treatment Failure	2019
Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer. Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2019
Checkpoint Inhibitor-TKI Combos Effective in RCC. Cancer discovery, 2019, Volume: 9, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Sunitinib	2019
External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib. International journal of clinical oncology, 2019, Volume: 24, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nomograms; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate	2019
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). The oncologist, 2019, Volume: 24, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Pyrimidines; Quality of Life; Sulfonamides; Survival Rate; Treatment Outcome; Young Adult	2019
Noninvasive Contrast-Free 3D Evaluation of Tumor Angiogenesis with Ultrasensitive Ultrasound Microvessel Imaging. Scientific reports, 2019, 03-20, Volume: 9, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Blood Flow Velocity; Carcinoma, Renal Cell; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Contrast Media; Humans; Image Interpretation, Computer-Assisted; Indazoles; Kidney Neoplasms; Microvessels; Models, Biological; Neovascularization, Pathologic; Phantoms, Imaging; Proof of Concept Study; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Ultrasonography	2019
Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy. Targeted oncology, 2019, Volume: 14, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Molecular Targeted Therapy; Neutrophils; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate	2019
Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase Inhibitors. The oncologist, 2019, Volume: 24, Issue:7 Topics: Aged; Carcinoma, Renal Cell; Female; Heart Failure; Humans; Indazoles; Kidney Neoplasms; Leiomyosarcoma; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib	2019
Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution. Clinical genitourinary cancer, 2019, Volume: 17, Issue:3 Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom	2019
[Axitinib in real life, analysis of our results.] Archivos espanoles de urologia, 2019, Volume: 72, Issue:4 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Retrospective Studies; Treatment Outcome	2019
Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study. Clinical genitourinary cancer, 2019, Volume: 17, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Folic Acid; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome	2019
Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist? Cell death & disease, 2019, 05-28, Volume: 10, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter 1; Carcinoma, Renal Cell; Cell Proliferation; Cell Survival; Cholesterol; Drug Inverse Agonism; Fatty Acids; Humans; Indazoles; Kidney Neoplasms; Lipid Metabolism; Liver X Receptors; Mice; Mice, Nude; Receptors, LDL; Sulfonamides; Transplantation, Heterologous	2019
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. Clinical genitourinary cancer, 2019, Volume: 17, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Patient Safety; Prognosis; Prospective Studies; Pyrimidines; Risk Factors; Sulfonamides; Survival Rate; Young Adult	2019
Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical genitourinary cancer, 2019, Volume: 17, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Precision Medicine; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome	2019
Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study. Clinical genitourinary cancer, 2019, Volume: 17, Issue:5 Topics: Aged; Antineoplastic Agents; Austria; Carcinoma, Renal Cell; Clinical Decision-Making; Electronic Health Records; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sex Characteristics; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2019
Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. International journal of radiation oncology, biology, physics, 2019, 10-01, Volume: 105, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Confidence Intervals; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pyrimidines; Quality of Life; Radiosurgery; Regression Analysis; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Tomography, X-Ray Computed	2019
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. Journal of clinical pharmacology, 2013, Volume: 53, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Young Adult	2013
New options for second-line therapy of advanced renal cancer. The Lancet. Oncology, 2013, Volume: 14, Issue:6 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib	2013
[Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides	2013
Urological cancer: second-line option for metastatic RCC. Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors	2013
Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-01, Volume: 19, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Synergism; Female; Gene Expression; Humans; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Pyrimidines; Pyrroles; Sirolimus; Stearoyl-CoA Desaturase; Sulfonamides; Sunitinib; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays	2013
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2013, Volume: 71, Issue:9 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid	2013
Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC. Nature reviews. Urology, 2013, Volume: 10, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors	2013
Axitinib controlled metastatic renal cell carcinoma for 5 years. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:7 Topics: Aged; Antineoplastic Agents; Asian People; Axitinib; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Seizures; Tomography, X-Ray Computed; Treatment Outcome	2013
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:15 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides	2013
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib	2013
[Frequent gout attacks during therapy - what can be done?]. MMW Fortschritte der Medizin, 2013, May-16, Volume: 155, Issue:9 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Colchicine; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides	2013
Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain. BMC cancer, 2013, Sep-02, Volume: 13 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Decision Making, Organizational; Health Care Costs; Humans; Incidence; Indazoles; Kidney Neoplasms; Markov Chains; Neoplasm Staging; Prevalence; Pyrimidines; Spain; Sulfonamides	2013
[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer]. Magyar onkologia, 2013, Volume: 57, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Humans; Hungary; Hypertension; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Treatment Outcome	2013
Targeted therapies: treating advanced kidney cancer-miles to go before we sleep. Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:11 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides	2013
Reversible posterior leukoencephalopathy syndrome induced by axitinib. Clinical genitourinary cancer, 2014, Volume: 12, Issue:1 Topics: Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Middle Aged; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2014
Statistical and practical considerations for clinical evaluation of predictive biomarkers. Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins	2013
Axitinib dose titration: what's the limiting factor? The Lancet. Oncology, 2013, Volume: 14, Issue:12 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors	2013
Radiation recall dermatitis induced by pazopanib. Onkologie, 2013, Volume: 36, Issue:11 Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Radiodermatitis; Radiotherapy, Conformal; Sulfonamides; Treatment Outcome	2013
Axitinib in advanced renal-cell carcinoma. The Lancet. Oncology, 2013, Volume: 14, Issue:13 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib	2013
Kidney cancer: Axitinib destined for second place? Nature reviews. Urology, 2013, Volume: 10, Issue:12 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors	2013
Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report. BMC research notes, 2013, Nov-24, Volume: 6 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Neoplasm Grading; Nephrectomy; Protein Kinase Inhibitors; Radiography; Treatment Outcome	2013
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. International urology and nephrology, 2014, Volume: 46, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobin A; Humans; Indazoles; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A	2014
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2014
Axitinib-induced acute pancreatitis: a case report. Anti-cancer drugs, 2014, Volume: 25, Issue:4 Topics: Acute Disease; Adult; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Pancreatitis; Protein Kinase Inhibitors	2014
Pazopanib outscores sunitinib on tolerability. Cancer discovery, 2014, Volume: 4, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib	2014
Axitinib. Prescrire international, 2013, Volume: 22, Issue:143 Topics: Axitinib; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2013
Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer research, 2014, Volume: 34, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides	2014
Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy? Cancer biology & therapy, 2014, Volume: 15, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds	2014
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clinical genitourinary cancer, 2014, Volume: 12, Issue:5 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Treatment Outcome	2014
Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:4 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Hepatic Veins; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior	2014
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. European urology, 2014, Volume: 66, Issue:3 Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid	2014
Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better? European urology, 2014, Volume: 66, Issue:5 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Laparoscopy; Male; Neoadjuvant Therapy; Nephrectomy; Protein Kinase Inhibitors	2014
Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib. Clinical genitourinary cancer, 2014, Volume: 12, Issue:4 Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Myasthenia Gravis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Uveal Neoplasms	2014
Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:7 Topics: Adolescent; Adult; Aged; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Young Adult	2014
How to interpret patient preferences in selecting the best drug: are the current measurements up to the job? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, May-10, Volume: 32, Issue:14 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2014
[Metastasized renal cell carcinoma - research subjects needed!]. Aktuelle Urologie, 2014, Volume: 45, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Metastasis; Niacinamide; Patient Selection; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides	2014
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy. Journal of surgical oncology, 2014, Volume: 110, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis	2014
Kidney cancer: progress and controversies in neoadjuvant therapy. Nature reviews. Urology, 2014, Volume: 11, Issue:5 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Neoadjuvant Therapy; Nephrectomy; Protein Kinase Inhibitors	2014
Editorial comment to activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:7 Topics: Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clinical genitourinary cancer, 2014, Volume: 12, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2014
Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:6 Topics: Age Factors; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Comorbidity; Databases, Factual; Drug Prescriptions; Drug Utilization Review; Female; Humans; Indazoles; Insurance Claim Reporting; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome; United States	2014
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. Clinical genitourinary cancer, 2014, Volume: 12, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2014
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Eosinophils; Female; Hemoglobins; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2014
In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2014
Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanib. The British journal of dermatology, 2014, Volume: 171, Issue:6 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Humans; Indazoles; Kidney Neoplasms; Lupus Erythematosus, Cutaneous; Male; Pyrimidines; Sulfonamides	2014
BAI, a novel Cdk inhibitor, enhances farnesyltransferase inhibitor LB42708-mediated apoptosis in renal carcinoma cells through the downregulation of Bcl-2 and c-FLIP (L). International journal of oncology, 2014, Volume: 45, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Membrane Potential, Mitochondrial; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Thiazolidines	2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. The Journal of urology, 2015, Volume: 193, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2015
Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib. Anti-cancer drugs, 2015, Volume: 26, Issue:1 Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Esophageal Neoplasms; Gastric Fundus; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Stomach Neoplasms; Sulfonamides	2015
Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:6 Topics: Animals; Axitinib; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Imidazoles; Indazoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2014
[Effective treatment of metastatic rhabdomyosarcoma with pazopanib]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:8 Topics: Angiogenesis Inhibitors; Biopsy, Needle; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Peritoneal Neoplasms; Pyrimidines; Rhabdomyosarcoma; Sulfonamides	2014
What next? Choosing second-line therapy in progressive renal cell carcinoma. Oncology (Williston Park, N.Y.), 2014, Volume: 28, Issue:9 Topics: Aged; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Radiography; Spinal Neoplasms; Sulfonamides	2014
Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile. The Journal of urology, 2015, Volume: 193, Issue:4 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Time Factors; Treatment Outcome	2015
Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib. Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:4 Topics: Antineoplastic Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2015
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. British journal of cancer, 2014, Nov-11, Volume: 111, Issue:10 Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Neoplasm Staging; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Rate; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-2	2014
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Molecular cancer therapeutics, 2015, Volume: 14, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Mice; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2015
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jan-15, Volume: 21, Issue:2 Topics: Adolescent; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Genome-Wide Association Study; Humans; Indazoles; Kidney Neoplasms; Male; Polymorphism, Single Nucleotide; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2; Young Adult	2015
Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib. International journal of clinical oncology, 2015, Volume: 20, Issue:4 Topics: Aged; Antineoplastic Agents; Asian People; Axitinib; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proteinuria; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies	2015
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. European urology, 2015, Volume: 68, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Withholding Treatment	2015
First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. Clinical genitourinary cancer, 2015, Volume: 13, Issue:3 Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Community Networks; Electronic Health Records; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; United States; Young Adult	2015
Health care costs among renal cancer patients using pazopanib and sunitinib. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:1 Topics: Carcinoma, Renal Cell; Female; Health Care Costs; Health Services; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; United States	2015
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:1 Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Pyrimidines; Pyrroles; Quality of Life; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis; United States	2015
[Presurgical treatment of axitinib reduced operation risk by downsizing the vena cava tumor thrombus in advanced renal cell carcinomas: two case reports]. Hinyokika kiyo. Acta urologica Japonica, 2014, Volume: 60, Issue:12 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Preoperative Care; Protein Kinase Inhibitors; Vena Cava, Inferior	2014
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature, 2015, Mar-05, Volume: 519, Issue:7541 Topics: Angiogenesis Inhibitors; Axitinib; Cell Line; Cell Proliferation; Crystallization; Crystallography, X-Ray; Drug Repositioning; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Conformation; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Vascular Endothelial Growth Factor Receptor-2	2015
Kidney cancer, version 3.2015. Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:2 Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British journal of cancer, 2015, Mar-31, Volume: 112, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis; Young Adult	2015
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea. Cancer research and treatment, 2016, Volume: 48, Issue:1 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pyrimidines; Republic of Korea; Sulfonamides; Treatment Outcome	2016
Piloting international production of rapid relative effectiveness assessments of pharmaceuticals. International journal of technology assessment in health care, 2014, Volume: 30, Issue:5 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Comparative Effectiveness Research; Europe; Humans; Indazoles; International Cooperation; Kidney Neoplasms; Pilot Projects; Program Evaluation; Prohibitins; Pyrimidines; Sulfonamides; Surveys and Questionnaires; Technology Assessment, Biomedical	2014
[Spontaneous enterocutaneous and rectovaginal fistula: potential complications during therapy with anti-angiogenic drugs in renal cancer]. Archivos espanoles de urologia, 2015, Volume: 68, Issue:2 Topics: Angiogenesis Inhibitors; Female; Humans; Indazoles; Intestinal Fistula; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Rectovaginal Fistula; Sulfonamides	2015
Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma. Chinese clinical oncology, 2015, Volume: 4, Issue:1 Topics: Asia; Asian People; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome	2015
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Science translational medicine, 2015, Apr-08, Volume: 7, Issue:282 Topics: Administration, Metronomic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Kidney Neoplasms; Maximum Tolerated Dose; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Survival Analysis; Topotecan; Xenograft Model Antitumor Assays	2015
Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan. BMC urology, 2015, Apr-16, Volume: 15 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome	2015
Nasal tumoral lesion: challenge. Cutaneous metastasis of renal cell carcinoma. The American Journal of dermatopathology, 2015, Volume: 37, Issue:5 Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Fatal Outcome; Humans; Immunohistochemistry; Indazoles; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Nose Neoplasms; Pyrimidines; Skin Neoplasms; Sulfonamides; Time Factors; Treatment Outcome	2015
Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Heart Failure; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides	2016
Cost-effectiveness analysis of axitinib through a probabilistic decision model. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; Uncertainty	2015
Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States	2015
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. American journal of hypertension, 2016, Volume: 29, Issue:2 Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness	2016
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU international, 2016, Volume: 117, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome	2016
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. PloS one, 2015, Volume: 10, Issue:6 Topics: Apoptosis; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cytokines; Dendritic Cells; Dose-Response Relationship, Drug; Down-Regulation; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lymphocyte Activation; Monocytes; p38 Mitogen-Activated Protein Kinases; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-rel; STAT3 Transcription Factor; T-Lymphocytes; Vascular Endothelial Growth Factor A	2015
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications. The Canadian journal of urology, 2015, Volume: 22, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate	2015
Symptomatic cardiac metastasis responding to pazopanib in a patient with renal cell carcinoma. The Canadian journal of urology, 2015, Volume: 22, Issue:3 Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Heart Neoplasms; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Pyrimidines; Sulfonamides; Watchful Waiting	2015
Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works? Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7 Topics: Blood Pressure; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors	2015
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer immunology, immunotherapy : CII, 2015, Volume: 64, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Everolimus; Female; Humans; Immunotherapy; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Cells; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; T-Lymphocytes; Treatment Outcome	2015
Re: Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma. European urology, 2015, Volume: 68, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Laparoscopy; Male; Neoadjuvant Therapy; Nephrectomy; Protein Kinase Inhibitors	2015
Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma. Chinese medical journal, 2015, Aug-05, Volume: 128, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein; Young Adult	2015
Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2015, Volume: 18, Issue:5 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Comparative Effectiveness Research; Cooperative Behavior; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Europe; Humans; Indazoles; Insurance, Health, Reimbursement; International Cooperation; Kidney Neoplasms; Models, Economic; Prohibitins; Pyrimidines; Sulfonamides; Treatment Outcome	2015
Sequential molecularly targeted drug therapy including axitinib for a patient with end-stage renal failure and metastatic renal cell carcinoma. Hemodialysis international. International Symposium on Home Hemodialysis, 2016, Volume: 20, Issue:2 Topics: Antineoplastic Agents; Axitinib; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Renal Dialysis; Renal Insufficiency, Chronic	2016
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. Journal of oncology practice, 2015, Volume: 11, Issue:6 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Current medical research and opinion, 2015, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cohort Studies; Drug Costs; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medicare; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United States; Young Adult	2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib	2016
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Targeted oncology, 2016, Volume: 11, Issue:2 Topics: Axitinib; Carcinoma, Renal Cell; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Imidazoles; Indazoles; Kidney; Kidney Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic	2016
Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget, 2015, Nov-03, Volume: 6, Issue:34 Topics: Apoptosis; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Cellular Senescence; DNA Damage; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Killer Cells, Natural; Mitosis; Protein Kinase Inhibitors	2015
Geographical tongue induced by axitinib. BMJ case reports, 2015, Oct-16, Volume: 2015 Topics: Axitinib; Glossitis, Benign Migratory; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors	2015
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom	2016
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin Cancer, 2016, Feb-01, Volume: 122, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin BJU international, 2016, Volume: 118, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome	2016
Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report. Journal of medical case reports, 2015, Nov-19, Volume: 9 Topics: Antineoplastic Agents; Axitinib; Biopsy; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Female; Humans; Imidazoles; Indazoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Radiotherapy; Survivors; Tomography, X-Ray Computed	2015
Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:9 Topics: Animals; Antineoplastic Agents; Axitinib; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2016
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. Journal of medical economics, 2016, Volume: 19, Issue:5 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2016
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment	2016
Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma. International journal of clinical oncology, 2016, Volume: 21, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proteinuria; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome	2016
A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma. The Keio journal of medicine, 2015, Volume: 64, Issue:4 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Pancreatitis; Phenylurea Compounds; Sorafenib	2015
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Current medical research and opinion, 2016, Volume: 32, Issue:4 Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States	2016
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. European urology, 2016, Volume: 70, Issue:3 Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment	2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC). Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Brain Metastasis Responsive to Pazopanib in Renal Cell Carcinoma: A Case Report and Review of the Literature. Clinical genitourinary cancer, 2016, Volume: 14, Issue:4 Topics: Aged; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides	2016
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology, 2016, Volume: 90, Issue:3 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Cross-Over Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis	2016
Bullous fixed drug eruption in a patient with metastatic renal cell carcinoma induced by iodinated contrast during pazopanib treatment. European journal of dermatology : EJD, 2016, Apr-01, Volume: 26, Issue:2 Topics: Aged; Antineoplastic Agents; Blister; Carcinoma, Renal Cell; Contrast Media; Drug Eruptions; Hand Dermatoses; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Triiodobenzoic Acids	2016
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult	2016
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 07-15, Volume: 22, Issue:14 Topics: A549 Cells; Animals; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Crizotinib; HEK293 Cells; HT29 Cells; Humans; Immunoassay; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Small Molecule Libraries; Stomach Neoplasms; Sulfonamides; Sulfones; Xenograft Model Antitumor Assays	2016
[NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER]. Klinichna khirurhiia, 2015, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2015
[Systemic therapy of metastatic renal cell carcinoma]. Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:7 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2016
Pharmacokinetic Analysis of a Hemodialyzed Patient Treated With Pazopanib. Clinical genitourinary cancer, 2016, Volume: 14, Issue:4 Topics: Aged; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Renal Dialysis; Sulfonamides	2016
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. Oncotarget, 2016, Jun-21, Volume: 7, Issue:25 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Genotype; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Aged; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States	2016
Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets. Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:6 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Female; Humans; Imidazoles; Indazoles; Insurance Claim Review; Kidney Neoplasms; Male; Middle Aged; Pharmacy; Retrospective Studies; United States	2016
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. European urology, 2016, Volume: 70, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden	2016
Case of severe ulceration induced by pazopanib. The Journal of dermatology, 2017, Volume: 44, Issue:4 Topics: Adolescent; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2017
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget, 2016, Jul-05, Volume: 7, Issue:27 Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays	2016
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. BMC cancer, 2016, 06-11, Volume: 16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Netherlands; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult	2016
Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer medicine, 2016, Volume: 5, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Renal Cell; CD28 Antigens; Chemotherapy, Adjuvant; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Nephrectomy; Preoperative Period; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Vascular Endothelial Growth Factor A; Young Adult	2016
Tumor Thrombus of Renal Cell Carcinoma Extending Into the Inferior Vena Cava, Ovarian Vein, and Ureter Treated With Neoadjuvant Axitinib. Urology, 2016, Volume: 95 Topics: Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Ovary; Ureteral Neoplasms; Veins; Vena Cava, Inferior	2016
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Carcinoma, Renal Cell; Exome Sequencing; Female; Fumarate Hydratase; GRB2 Adaptor Protein; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult	2017
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Young Adult	2016
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3 Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Cohort Studies; Computer Communication Networks; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma. Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Retrospective Studies; Treatment Outcome	2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors	2016
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Retrospective Studies; Survival Analysis; Treatment Outcome	2017
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy. BMC cancer, 2016, 08-02, Volume: 16 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2016
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. BMC urology, 2016, Aug-02, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Republic of Korea; Retrospective Studies; Sulfonamides; Young Adult	2016
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European journal of cancer (Oxford, England : 1990), 2016, Volume: 65 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib	2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World journal of urology, 2017, Volume: 35, Issue:4 Topics: Algorithms; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Consensus; Decision Support Techniques; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Nivolumab; Protein Kinase Inhibitors; Pyridines; Treatment Failure	2017
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Oncotarget, 2016, Jun-21, Volume: 7, Issue:25 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays	2016
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker? Medical hypotheses, 2016, Volume: 94 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cholesterol; Ferritins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Indazoles; Indoles; Iron; Kidney Neoplasms; Lipids; Metabolome; Models, Theoretical; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Triglycerides	2016
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. International journal of clinical oncology, 2017, Volume: 22, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors	2017
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clinical genitourinary cancer, 2017, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult	2017
Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:4 Topics: Adult; Aged; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Carcinoma, Renal Cell; Female; Genotype; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Retrospective Studies; Treatment Failure	2016
[Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases]. Archivos espanoles de urologia, 2016, Volume: 69, Issue:7 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Sunitinib	2016
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Tumor Burden	2017
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2016, Sep-23, Volume: 38, Issue:9 Topics: Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. Anti-cancer drugs, 2017, Volume: 28, Issue:2 Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Rate	2017
[Metastatic Renal Cell Carcinoma in Paranasal Sinus for which Periodic Drug Withdrawal Schedule of Axitinib was Effective : A Case Report]. Hinyokika kiyo. Acta urologica Japonica, 2016, Volume: 62, Issue:9 Topics: Axitinib; Carcinoma, Renal Cell; Imidazoles; Indazoles; Kidney Neoplasms; Nephrectomy; Nose Neoplasms; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome	2016
[A Case of Renal Cell Carcinoma with Malignant Pleural Effusion Showing Marked Response to Axitinib]. Hinyokika kiyo. Acta urologica Japonica, 2016, Volume: 62, Issue:10 Topics: Adult; Axitinib; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Nephrectomy; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Tomography, X-Ray Computed	2016
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity. BMC medicine, 2016, Dec-07, Volume: 14, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Genetic Heterogeneity; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pharmacogenomic Testing; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib	2016
Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site. Clinical genitourinary cancer, 2017, Volume: 15, Issue:4 Topics: Adult; Aged; Carcinoma, Renal Cell; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pyrimidines; Sensitivity and Specificity; Sulfonamides; Treatment Outcome	2017
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report. The American journal of case reports, 2017, Jan-03, Volume: 18 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome	2017
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult	2017
First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. Clinical genitourinary cancer, 2017, Volume: 15, Issue:4 Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Indazoles; Italy; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome	2017
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis. Clinical genitourinary cancer, 2017, Volume: 15, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; SEER Program; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2017
Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective. Clinical therapeutics, 2017, Volume: 39, Issue:3 Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Humans; Indazoles; Indoles; Italy; Kidney Neoplasms; National Health Programs; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis	2017
Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. The Journal of urology, 2017, Volume: 197, Issue:3 Pt 1 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Sunitinib	2017
[A Case of Hydrocephalus Due to Brain Metastasis from Renal Cell Carcinoma Successfully Treated with Axitinib]. Hinyokika kiyo. Acta urologica Japonica, 2017, Volume: 63, Issue:1 Topics: Aged; Axitinib; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Hydrocephalus; Imidazoles; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Multimodal Imaging; Nephrectomy; Protein Kinase Inhibitors; Tomography, X-Ray Computed	2017
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:4 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome	2017
Kidney cancer: Reversal of fortunes for TKI resistance. Nature reviews. Urology, 2017, Volume: 14, Issue:5 Topics: Angiogenesis Inhibitors; Benzofurans; Histone Deacetylases; Humans; Hydroxamic Acids; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2017
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. Clinical nuclear medicine, 2017, Volume: 42, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib	2017
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. The Journal of urology, 2008, Volume: 180, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease	2008
Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-20, Volume: 27, Issue:3 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Erythropoietin; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases	2009
Pazopanib. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides	2010
New weapons against kidney cancer. Two recent drug options appear to extend survival for kidney cancer patients who can't tolerate existing medications. DukeMedicine healthnews, 2010, Volume: 16, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2010
Prognostic factors in patients treated with VEGF-targeted therapies. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factors	2010
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. British journal of cancer, 2010, Apr-27, Volume: 102, Issue:9 Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Bilirubin; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Genotype; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kidney Neoplasms; Liver; Male; Middle Aged; Nephrectomy; Polymorphism, Genetic; Pyrimidines; Sulfonamides	2010
Everolimus and pazopanib: two new drugs for renal cell cancer. The Medical letter on drugs and therapeutics, 2010, May-03, Volume: 52, Issue:1337 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Interactions; Everolimus; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sirolimus; Sulfonamides	2010
Pazopanib in renal cell carcinoma. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2010
Pazopanib trial data cannot support first-line use. Nature reviews. Urology, 2010, Volume: 7, Issue:6 Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2010
Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:7 Topics: Clinical Trials as Topic; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome	2010
Is advanced renal cell carcinoma becoming a chronic disease? Lancet (London, England), 2010, Aug-21, Volume: 376, Issue:9741 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Protein Serine-Threonine Kinases; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2010
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. Expert opinion on biological therapy, 2010, Volume: 10, Issue:11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2010
NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma. The Lancet. Oncology, 2011, Volume: 12, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2011
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Cross-Over Studies; Disease-Free Survival; DNA Mutational Analysis; Genetic Markers; Genotype; Germ-Line Mutation; Humans; Indazoles; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Proteins; Neovascularization, Physiologic; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrimidines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sulfonamides	2011
Pazopanib. Kidney cancer: many risks, but is there a benefit for patients? Prescrire international, 2011, Volume: 20, Issue:114 Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2011
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urologie, 2011, Volume: 42, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS. Clinical genitourinary cancer, 2011, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Management; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sirolimus; Treatment Failure	2011
Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report. Clinical genitourinary cancer, 2011, Volume: 9, Issue:2 Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Differentiation; Female; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2011
Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. The Canadian journal of urology, 2011, Volume: 18, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Indazoles; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2011
Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma. Clinical journal of oncology nursing, 2011, Volume: 15, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indazoles; Kidney Neoplasms; Nursing Methodology Research; Oncology Nursing; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides	2011
[Pharmacological sheet: pazopanib (Votrient), oral administration]. Journal de pharmacie de Belgique, 2011, Issue:3 Topics: Antineoplastic Agents; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2011
Tilting the AXIS towards therapeutic limits in renal cancer. Lancet (London, England), 2011, Dec-03, Volume: 378, Issue:9807 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2011
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult	2012
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report. Anticancer research, 2012, Volume: 32, Issue:2 Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib	2012
Second-line treatment for renal cell cancer. British journal of cancer, 2012, Feb-14, Volume: 106, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Retreatment; Sulfonamides; Sunitinib	2012
Nursing considerations for patients receiving pazopanib for renal cell carcinoma. ONS connect, 2012, Volume: 27, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides	2012
Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. Clinical genitourinary cancer, 2012, Volume: 10, Issue:2 Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A	2012
Case of complete response to everolimus for metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:9 Topics: Abdominal Cavity; Acute Kidney Injury; Axitinib; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Imidazoles; Immunosuppressive Agents; Indazoles; Interferon-alpha; Kidney Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Tomography, X-Ray Computed; Withholding Treatment	2012
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis	2012
Axitinib (Inlyta) for advanced renal cell carcinoma. The Medical letter on drugs and therapeutics, 2012, Jun-11, Volume: 54, Issue:1392 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms	2012
Biomarkers in personalised treatment of renal-cell carcinoma. The Lancet. Oncology, 2012, Volume: 13, Issue:8 Topics: Angiogenic Proteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cytokines; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2012
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. The Lancet. Oncology, 2012, Volume: 13, Issue:8 Topics: Angiogenic Proteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cluster Analysis; Cytokines; Disease-Free Survival; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Linear Models; Logistic Models; Multicenter Studies as Topic; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Tumor Burden	2012
Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-20, Volume: 30, Issue:27 Topics: Aged; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor A	2012
Reversible posterior leukoencephalopathy syndrome induced by pazopanib. BMC cancer, 2012, Oct-22, Volume: 12 Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides	2012
Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid : official journal of the American Thyroid Association, 2013, Volume: 23, Issue:4 Topics: Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Thyroid Function Tests; Thyroiditis; Thyrotoxicosis; Thyrotropin	2013
Active tuberculosis during temsirolimus and bevacizumab treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-10, Volume: 31, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Sirolimus; Tuberculosis	2013
Axitinib: in advanced, treatment-experienced renal cell carcinoma. Drugs, 2012, Dec-24, Volume: 72, Issue:18 Topics: Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome	2012
Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma. Journal of clinical pharmacy and therapeutics, 2013, Volume: 38, Issue:2 Topics: Aged; Carcinoma, Renal Cell; Humans; Immunosuppressive Agents; Indazoles; Kidney Neoplasms; Male; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor A	2013
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clinical genitourinary cancer, 2013, Volume: 11, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States	2013
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position. Clinical genitourinary cancer, 2013, Volume: 11, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome	2013
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer treatment reviews, 2013, Volume: 39, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2013
Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-01, Volume: 31, Issue:7 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Nephrectomy; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome	2013
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. American journal of clinical oncology, 2014, Volume: 37, Issue:4 Topics: Axitinib; Carcinoma, Renal Cell; Diarrhea; Dysphonia; Fatigue; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Nausea; Protein Kinase Inhibitors; Proteinuria; Vomiting	2014
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute, 2003, Apr-02, Volume: 95, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell Hypoxia; Culture Media, Conditioned; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; G(M1) Ganglioside; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Indazoles; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lymphokines; Male; Mice; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Neuroblastoma; Platelet Endothelial Cell Adhesion Molecule-1; Precipitin Tests; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Transcription Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU international, 2006, Volume: 98, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Mutation; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease	2006
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer, 2007, Aug-01, Volume: 110, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A	2007
Targeting VEGF receptors in kidney cancer. The Lancet. Oncology, 2007, Volume: 8, Issue:11 Topics: Axitinib; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Mutation; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Von Hippel-Lindau Tumor Suppressor Protein	2007